Implantable device for the locationally accurate delivery and administration of substances into the pericardium or onto the surface of the heart

ABSTRACT

The present invention relates to a device for the administration of substances onto the epicardial surface of the heart. The device comprises a frame structure which is able to assume shaping, positioning, guiding and stabilizing functions. The frame structure may contain at least one sleeve. The device comprises a substance carrier which is able to accommodate the substance to be administered.

PRIORITY CLAIM

The present application claims priority to German patent applicationserial no. DE 102015212699.4, filed Jul. 7, 2015, the entire contents ofwhich is incorporated herein by reference and relied upon.

BACKGROUND

The invention is for use in the treatment of cardiac insufficiency, forexample following previous myocardial infarction. It is intended tosupport the pumping function of the heart, increase it or regeneratedamaged heart tissue and hence to reduce insufficiency over the mediumand long term or prevent the terminal stage being reached.

Cardiovascular diseases such as terminal cardiac insufficiency ormyocardial infarction are the main cause of death worldwide (Behfar, A.and A. Terzic. Nature clinical practice Cardiovascular medicine 3 Suppl1, pp. 78-82, 2006). 32% of worldwide deaths are the result ofcardiovascular diseases (World Health Statistics,http://apps.who.int/iris/bitstream/10665/81965/1/9789241564588_eng.pdf(2013)2013). 40% of all deaths in Germany are attributable tocardiovascular diseases (German Federal Office of Statistics,https://www.destatis.de/DE/Publikationen/Thematisch/Gesundheit/Todesursachen/Todesursachen.html,2013). In the USA, around a million people a year suffer a heart attackand six million suffer resulting cardiac insufficiency; the direct andindirect costs of this are estimated at 180 billion dollars a year(Christoforou et al., Plos One 8, 17, 2013). The medical, societal andeconomic implications are enormous and are set to increase worldwideover the coming years as a result of our growing prosperity, thelifestyle associated with it and demographic growth.

Cardiac insufficiency is described as a restriction of the pumpingfunction of the heart. The primary symptom is reduced pumpingperformance of the heart. The deterioration in performance iscompensated for by an increase in the volume of the heart. As a result,the thickness of the wall of the heart decreases, contractility fallsand pumping performance therefore declines further. This downward spiralculminates in heart failure or the failure of other organs owing to alack of oxygen and nutrients.

The various manifestations of cardiac insufficiency can be treatedthrough medication (for example through administration of beta blockers)or by carrying out an operation. The only treatment option for terminalcardiac insufficiency is a heart transplant.

However, there is a large demand for donor hearts and only insufficientsupply (Sasaki, D. and T. Okano, Embryonic Stem Cells—Recent Advances inPluripotent Stem Cell-Based Regenerative Medicine, 65-80, 2011).Pacemakers can compensate for disruptions in stimulus conduction,prostheses can replace defective heart valves and blood pumps (forexample ventricular assist devices, VADs) can improve the performance ofinsufficient hearts. However, the above methods only delay thedevelopment of insufficiency, they do not stop it or cure the disease(Christoforou et al., 2013). A treatment which addresses the variouscauses of cardiac insufficiency is to support the pumping function ofthe heart by means of an implant which exerts a mechanical pressure onthe heart and thereby improves its pumping performance not onlyimmediately but also over the medium and long term.

For example, cardiac insufficiency may develop as a result of a heartattack. In a heart attack, the sudden closure of at least one coronaryartery leads to the death of heart muscle cells. The limited ability ofthe damaged heart muscle tissue to regenerate prevents full andindependent recovery. Instead, dead tissue is replaced by scar tissuewhich is unable to contract. The pumping performance of the heartdeteriorates and the spiral of degeneration described above begins.

There is a medical, societal and economic need to develop effective,regenerative forms of treatment which support and increase the existingpumping function of the heart, prevent the formation of scar tissuefollowing a heart attack, promote the regeneration of heart muscle cellsand consequently prevent terminal cardiac insufficiency and heartfailure.

Previously known mechanical cardiac support devices are disclosed, forexample, in US patents U.S. Pat. No. 5,749,839 B1 and U.S. Pat. No.6,626,821 B1 and in WO application 00/25842. They disclose devices whichhave the disadvantage that their implantation requires an open-chestoperation. They are also complex and can only be implanted by means of acomplicated surgical operation. They are integrated into the bloodstreamof the patient. Improved centrifugal pumps or magnetically mountedimpeller systems continually convey the blood. Contact between the bloodand the exogenous surfaces of the systems is a considerable technicaland medical challenge. Common complications of these systems arestrokes, internal bleeding and infections. They often result inlong-term hospitalization and frequent readmission of patients who havejust been released from hospital.

Other known cardiac support devices, such as the devices disclosed in US2008/0021266 A1, DE 10 2009 043 795 A1, US 2004/0267329 A1, US2005/0107661 A1, US 2006/0217774 A1, US 2007/0197859 A1, US 2009/0036730A1, US 2011/0021864 A1, U.S. Pat. No. 8,944,987 B2 and EP 2482865 B1,have the disadvantage that no embodiments exist which prevent thespatial impairment of the inferior vena cava by the implanted device.The inferior vena cava opens from the back into the right atrium.Spatial impairment of the inferior vena cava by the device would lead toinferior cava syndrome (obstruction of the filling of the right atrium).A further disadvantage of known cardiac support systems is that noprecautions are taken against dislocation of the device in relation tothe heart. Dislocation leads to a poorer fit of the device to the heartand to a loss of support. Nor are any of these devices self-expanding,that is to say they can only be put into their target position, in whichthey surround the heart, with the aid of further devices.

Other known cardiac support systems, such as the devices disclosed in EP2752208 A1, are self-expanding and have a recess which prevents theinferior vena cava or other anatomical features near the heart frombeing spatially impaired, but they lack the ability to administersubstances, such as pharmaceutical active agents, locationallyaccurately and in a targeted manner onto the epicardium.

A promising approach to the regenerative treatment of ischaemic tissueafter a heart attack is through treatment with stem cells (Vizzardi, E.et al. J. Card. Surg., 53, 685-689, 2012) or with what are referred toas growth factors (Korf-Klingebiel, M. et al., Nature Medicine 21,52-61, 2015). Under certain conditions, stem cells can identifycardiomyocytes and replaced dead cells (Sasaki and Okano, 2011). Stemcells have hitherto with little therapeutic success primarily beeninjected into the bloodstream (US 2009/0285787 A1) or released in thecoronary artery via a catheter (U.S. Pat. No. 8,372,054 B2, US20070065414 A1, US 20120157751 A1, US 20140072611 A1). Only a smallproportion of cells (˜3%) or other therapeutic substances reaches thetarget location (Hou, D. M. et al. Circulation 112, 1150-1156, 2005).Injecting cells into the coronary artery can lead to the artery becomingblocked. All of the above methods work by releasing cells or therapeuticsubstances in the bloodstream which may lead to internal bleeding,infections, thrombus formation and hence heart attacks and strokes.Another form of administration is the injection of cells into themyocardium (U.S. Pat. No. 6,659,950 B2, US 20100168713 A1). Because ofthe movement of the heart, these methods carry a high risk of tissue orvascular damage and of wrongly administered injections without resultingin more successful treatment (Jawad, H., A. R. Lyon, S. E. Harding, N.N. Ali and A. R. Boccaccini, 2008, Myocardial tissue engineering.British Medical Bulletin, 87, 31-47). In order to increase therapeuticefficiency, it is also often necessary to administer, in addition,chemical signalling substances in a temporally and locationally definedmanner, which is impossible using said methods. None of the discloseddevices can administer substances via an implantable device into thepericardial cavity or onto the surface of the heart. Nor can any of thedisclosed devices deliver or remove substances already administered tothe pericardial cavity after implantation.

A device which overcomes all of these disadvantages is described here.The present invention relates to a device for supporting and restoringthe function of a heart. One aspect of the invention is a device for thelocationally accurate delivery of substances onto the surface of theheart or into the pericardial cavity, which does not have thedisadvantages of the known devices and/or methods for the administrationof therapeutic substances for the regeneration of ischaemic heart tissueafter a myocardial infarction. The device may be implanted minimallyinvasively with the aid of a catheter. It is not inserted into anyvascular system and therefore does not permanently come into directcontact with the blood, which considerably reduces the risk ofinfection, thrombus formation and internal bleeding compared to othersystems for administering substances for the regeneration of ischaemictissue after a heart attack. The device may remain in the body for acertain amount of time and be explanted minimally invasively aftertreatment has come to an end.

SUMMARY OF THE INVENTION

The device for administering a substance to a surface of the heartcomprises a frame structure, a sleeve, a substance carrier and asubstance to be administered. The device may also comprise an expandableunit which is mounted at, in or on the sleeve. The expandable unit mayalso be part of the sleeve. The substance carrier may be mounted on theexpandable unit or on the sleeve. Mounting the substance carrier on theexpandable unit allows administration of the substance with thesimultaneous exertion of pressure onto the surface of the heart.

The frame structure may be reversibly self-expanding. It may beincorporated minimally invasively into the body and may at leastpartially surround a heart in its expanded state.

The substance carrier may be a pocket. The substance to be administeredmay be inserted into the pocket. The substance may be inserted directlyinto the pocket or be applied to a carrier which is inserted into thepocket.

The pocket may have a removal area on the surface of the pocket facingthe heart. In some embodiments, the removable area may be removed fromoutside the body after implantation of the device. The removable areamay be at least partially biodegradable. The pocket may also comprise apermeable area.

The substance carrier may have a delivery line for filling and emptyingthe substance carrier with a substance to be administered. The substancecarrier may have a spongy or porous structure. This increases thesurface area and storage capacity of the substance carrier. Such astructure is also advantageous when administering cells because cellsadhere and/or proliferate better in such structures.

The sleeve may be affixed to the frame structure. The device may beimplanted minimally invasively. The frame structure may also be made outof wire, in particular out of a wire comprising a shape memory alloy.

The substance to be administered may be a pharmaceutical active agent.The substance to be administered may additionally or alternativelycomprise cells.

Embodiments of the present invention comprise a supply unit. This maycomprise a substance reservoir.

A further aspect of the invention relates to a device for implanting thedevice. The device for implanting may comprise a tubular deliverysystem. The tubular delivery system may have a distal end face which isslanted. This may facilitate implantation.

A further aspect of the invention relates to a device for explanting thedevice. The device for explanting may comprise a cylindrical tube,wherein the cylindrical tube is able to comprise a radial widening atthe distal end. This explantation device is able to allow the removal ofthe implant minimally invasively from the pericardial cavity

A further aspect relates to a method for producing a device for theadministration of a substance onto a surface of the heart. The methodcomprises the steps of providing a frame structure, mounting a sleeve onthe frame structure, mounting a substance carrier and filling thesubstance carrier with a substance to be administered. The substancecarrier may be mounted on the sleeve. The device may comprise anexpandable unit. The substance carrier may be mounted on the expandableunit.

The device for the administration of a substance onto a surface of theheart may comprise further components. For example, lines may beprovided for delivering and discharging the substance to beadministered. Mechanical forces may also be exerted on the administeredsubstances or the epicardial heart surface of the myocardium. The forcesmay be built up by the expandable units. Alternatively or in addition,forces may be built up on the substance carrier which improveadministration.

A further aspect relates to a motor unit which, by means of an electricmotor, drives a pressure reservoir of variable volume in order to setthe degree of expansion of the at least one expandable unit.

Furthermore, some embodiments of the device according to the inventionmay be energetically passive, that is to say they function without anyenergy supplied from outside and/or inside the body.

A further aspect of the device according to the invention is the factthat it may have devices which minimize the risk of damage to thesurrounding tissue caused by pointed or sharp-edged components of theframe structure produced in the manufacturing process.

Further embodiments and advantages are disclosed in the detaileddescription.

DESCRIPTION OF THE DRAWINGS

FIG. 1 shows a human torso with components of the implanted devicehaving an extracorporeal supply unit.

FIG. 2 shows an embodiment of the implant in the expanded and sealedstate in which it partially surrounds a heart and lies inside thepericardium.

FIG. 3 shows a section through a heart having an infarction which isheld by an inflatable, pneumatic chamber and substance carrier locatedthereon.

FIG. 4 shows a supply unit of an implant.

FIG. 5 shows a multiconnector with which the cable harness of an implantmay be coupled to a supply unit.

FIG. 6 shows the process for inserting a sluice into the pericardium.

FIG. 7 shows an assembly consisting of a sluice, a delivery systeminserted into it and an embodiment of the implant inserted therein. Theprocess for bringing the implant out into the pericardium is shown.

FIG. 8 shows a three-dimensional and an unrolled view of the expandableframe structure.

FIG. 9 shows a slotted tube with the pattern indicated and the processfor fitting the slotted tube onto a mandrel.

FIG. 10 shows an embodiment of an implant in which a substance carrierin the form of a pocket is mounted on a pneumatic chamber on the insideof a sleeve.

FIG. 11 shows various possible embodiments of the substance carrier.

FIG. 12 shows two general views of embodiments in which the substancecarrier is coupled directly to the pneumatic chamber.

FIG. 13 shows a substance carrier in the form of a fillable andemptyable pouch mounted on the front of a pneumatic chamber.

FIG. 14 shows various embodiments which serve to generate a tension inthe substance carrier.

FIG. 15 shows embodiments of an actuator unit for changing the degree ofexpansion of an expandable unit of the implant.

FIG. 16 shows a fully implantable embodiment of the device without acable harness or supply unit.

FIG. 17 shows various embodiments of end fittings and a frame structuregeometry which minimize the risk of damage to the body tissue caused bythe frame structure or the risk of the frame structure penetrating thesleeve at least partially surrounding it.

FIG. 18 shows an apparatus for explanting the device minimallyinvasively during the explantation process.

DETAILED DESCRIPTION

Embodiments of the invention comprise several components which areexplained in more detail in the following sections, it being possiblefor embodiments of the individual components to be combined with oneanother.

FIG. 1 shows a human torso with an embodiment (1) of the deviceaccording to the invention in the implanted state. The implant (100)comprises a frame structure (1), a sleeve (2) inserted therein, at leastone expandable unit (positioned on the sleeve (2) and/or the framestructure (1)) and at least one substance carrier, at least one sensorand at least one electrode. Also ascribed to the implant (100) are apericardium sluice (3), the implanted part of a cable harness (4) andpneumatic/hydraulic substance lines and electric lines inside the body.The embodiment (1) of the device according to the invention alsocomprises a supply unit (5). A control unit (6) and a monitoring unit(7) are also depicted. Embodiments of the device according to theinvention may be implanted at least partially in a human body. However,it may also be implanted in the body of an animal. Embodiments of thedevice according to the invention may be implanted in the body of amammal, for example the body of a dog, cat, rodent, primate,artiodactyl, perissodactyl or marsupial. Depending on the species,special adjustments may have to be made to the shape and functioning ofthe implant (100), the cable harness (4) and the supply unit (5) inorder to match the anatomy and/or physiology of the species concerned.The device comprises a frame structure (1) at least partiallysurrounding the heart (900). Also depicted is an encased cable harness(4) which exits from inside the body and is connected to a supply unit(5). Not depicted in FIG. 1 are, for example, a sleeve (2) that may beinserted into this frame structure (1) or further components that aremounted onto the surface of the sleeve (2) or are incorporated into itand may have a therapeutic effect. These are described elsewhere.

The frame structure (1) may be converted from a non-expanded state to anexpanded state for the purposes of implantation, which may also becarried out minimally invasively. In the expanded state, the framestructure (1) may at least partially surround a heart (900). In theexpanded state, the frame structure (1) may perform a shaping,positioning or stabilizing function or a combination thereof. In thenon-expanded state, the frame structure (1) may be inserted into adelivery system. The frame structure (1) may be a single part or mayalternatively consist of two, three, four, five, six or more parts. Theframe structure (1), which consists of at least one wire or at least onestrut, may be made at least partially out of a shape memory alloy.Materials for shape memory alloys are, for example, NiTi and NiTiFe(nickel-titanium and nickel-titanium-iron; nitinol), NiTiCu(nickel-titanium-copper), CuZn (copper-zinc), CuZnAl(copper-zinc-aluminium), CuAlNi (copper-aluminium-nickel), FeNiAl(iron-nickel-aluminium) and FeMnSi (iron-manganese-silicon). The framestructure (1) may also consist of titanium or titanium alloys, tantalumor tantalum alloys, stainless steel, polymer, polymer fibre material,carbon fibre material, aramide fibre material, glass fibre material orcombinations thereof. The frame structure (1) at least partiallysurrounds the heart (900) in the implanted state and is located insidethe pericardium. The frame structure (1) may also be mounted outside thepericardium. Such embodiments are not explained separately because thedescription applies to embodiments implanted both inside and outside thepericardium (apart from the pericardium sluice (3) which is omitted inthe case of an embodiment located outside the pericardium). The framestructure (1) may have at least one radiopaque marking with the aid ofwhich the positioning and orientation of the frame structure (1) inrelation to a heart (900) may be checked during and after implantation.The make-up of the frame structure (1) is explained in more detail inone of the following sections.

At least one sleeve (2) may be inserted into the frame structure (1).The sleeve (2) may be held by the frame structure (1). The sleeve (2)may be coupled to the frame structure (1). Alternatively, a framestructure (1) may be incorporated into a sleeve (2). The sleeve (2), thestructure thereof and the coupling between frame structure (1) andsleeve (2) are explained in more detail in one of the followingsections. Components with which a therapeutic effect may be achieved maybe inserted into the frame structure (1) or into the sleeve (2). Forexample, the therapeutic effect may be achieved by exerting mechanicalforces or by delivering substances onto the epicardium (the surface ofthe heart (900)).

FIG. 1 also shows a supply unit (5) which may be carried outside thebody. The supply unit (5) may also be partially or fully implanted inthe body. If the supply unit (5) is carried outside the body, it may beaffixed to a chest strap, to a hip belt or to an abdominal belt.Alternatively, it may be carried in a holster or on/in a rucksack. Otherforms of fixing or carrying are also conceivable. FIG. 1 also shows acable harness (4) which connects the supply unit (5) to the framestructure (1), to a sleeve (2) and/or to components inserted therein.The cable harness (4) is depicted encased in the present embodiment. Adetailed description of the cable harness (4) is provided in asubsequent section. If the supply unit (5) is carried outside the body,the cable harness (4) may enter the body at a given place. If the devicewith a frame structure (1), a sleeve (2), at least one expandable unitand at least one component for achieving a therapeutic effect is locatedinside the pericardial cavity (902), the cable harness (4) or partsthereof may be fed into the pericardial cavity (902). The cable harness(4) may be delivered to the point of entry into the body (905) and/or tothe point of entry (903) into the pericardial cavity (902) through apericardium sluice (3), which is explained in more detail in asubsequent section of the description.

If the at least one component having a therapeutic effect that isinserted serves the at least locationally accurate delivery to andadministration of substances onto the surface of the heart, at least oneline may be located in the cable harness (4), said line allowing thesubsequent delivery and/or discharge of a substance and/or a refillingof the substance in the inserted component.

If the at least one inserted component having a therapeutic effect isintended to exert a mechanical force on the surface of the heart, thisrequires the supply of energy from the supply unit (5). If the energy issupplied in the form of pneumatic or hydraulic energy, the cable harness(4) may contain at least one fluid line to transport pressurized fluid.If electrical energy has to be supplied, the cable harness (4) maycontain at least one electrical conductor. If the supply unit (5) iscarried outside the body, the electrical energy to be provided mayalternatively also be conveyed to the device in the body wirelessly, forexample using electromagnetic induction.

Alternatively, substances may also be administered and mechanical forcemay be exerted on the substance and/or the surface of the heart usingthe inserted component. In this case, at least one line may be providedfor subsequently delivering and/or discharging a substance and/orrefilling the substance and at the same time at least one fluid line orat least one electrical conductor may be provided.

If the device also contains at least one sensor, at least one electrodeor at least one electrical load (for example a heating coil) in theframe structure (1), in the sleeve (2), in the at least one expandableunit or in the inserted component having a therapeutic effect, the atleast one electrical line supplying the at least one sensor, electrodeor load may likewise be located in the cable harness (4).

There may be mounted, at the end of the cable harness (4), a plug partwhich may be connected to the supply unit (5) via a couplableconnection. Alternatively, a cable harness (4) with a plug part isprovided only on the supply unit (5). In this case, the connectioncouplable thereto is located on the implanted device.

The cable harness (4) may be a single continuous cable harness (4) or amulti-part cable harness (4). In the case of a multi-part cable harness(4), at least one further couplable pair of plugs may be located at anappropriate place in the cable harness (4). In the case of a multi-partcable harness (4), at least one part of the cable harness (4) may beremoved and at least one part of the cable harness (4) may remain on theimplanted device or the supply unit (5). The removable part of the cableharness (4) may serve as an extension cable and may be used if required.The device may then also be used without the extension cable and theremaining plug parts may be coupled to one another so that the devicemay be operated. In the case of a multi-part cable harness (4), theindividual cable harness pieces may be encoded, for exampleanalogue-electronically, for example by means of a resistor, ordigitally-electronically, for example using a ROM memory chip in theplug part. The supply unit (5) may read the encoding of the cableharness (4) and, if necessary, make adjustments in operation of thedevice. Such adjustments may, for example, be an increase in the supplyof fluid required on account of the use of an extension cable.

Embodiments of the device according to the invention may also haveseparate cable harnesses (4) for the line for subsequently deliveringand discharging substance, the fluid line or electrical line forsupplying energy to the inserted component having a therapeutic effectand/or the electrical line to provide energy for the at least onesensor, the at least one electrode or the at least one electrical load.If the supply unit (5) is connected directly to the at least oneinserted component having a therapeutic effect, the at least one sensor,the at least one electrode or the at least one electrical load, a cableharness (4) may alternatively be omitted.

One part of the continuous or multi-part cable harness (4), of theindividual cable harness (4) or of the cable harness (4) divided intoseveral cable harnesses (4) may run inside the body and another part mayrun outside the body. That part of the cable harness (4) that is insidethe body may be between 0 cm and 70 cm in length, or between 30 cm and60 cm in length. That part of the cable harness (4) that is outside thebody may be between 0 cm and 90 cm in length, or between 50 cm and 80 cmin length. The diameter of the cable harness (4) may be between 4 mm and25 mm, or between 6 mm and 12 mm. The multi-part cable harness (4) maybe advantageous compared to the continuous cable harness (4) because itis modular and therefore, for example, may allow a variable, possiblygreater freedom of movement of the patient.

The cable harness (4) may be surrounded by a fabric at least partiallyalong its longitudinal axis and at least partially circumferentially.The fabric may be porous, fibrous or rough. It may improve theengraftment of the cable harness (4) into the surrounding conjunctivetissue and hence the mechanical anchoring of the implanted deviceaccording to the invention in the body. It may, for example, consist offelt, expanded PTFE, Dacron or another suitable biocompatible syntheticfabric. However, the material of the fabric may differ from thisdepending on the intended use. For example, an additional screening ofthe cable harness (4) from the environment may also be possible, forexample in order to improve protection against irradiation andemissions.

FIG. 1 also shows an embodiment of a portable control unit (6) and alikewise portable monitoring unit (7). Embodiments of the deviceaccording to the invention may have a control unit (6) and a monitoringunit (7). It may also have just a control unit (6). It may also havejust a monitoring unit (7). It may also have neither a control unit (6)nor a monitoring unit (7). The control unit (6) and/or the monitoringunit (7) may redundantly assume functions already assumed by the supplyunit (5). They may alternatively also provide additional functions.

The control unit (6) may be designed as hardware with software playedthereon. The hardware may provide here at least one communicationinterface, at least one display and/or also the ability to reproduceacoustic, visual or haptic signals. The software played on this hardwaremay assume control, monitoring and communication functions. However, theexternal control unit (6) may alternatively also use third-partysupplier hardware and may merely be present in the form of a softwarepackage or an application (“app”). If the latter is the case, thecommunication interfaces provided by the third-party supplier hardwaremay be used in order to communicate with the information/control unit(6) or the supply unit (5). Communication may be carried out here via awireless P2P connection, a Bluetooth connection, a WLAN connection orsome other wireless form of data transmission. Alternatively,communication may also be carried out using wires. The control unit (6)may also assume an additional or exclusive monitoring function. Forexample, the data gathered by the at least one sensor of the implant(100) may be sent to the control unit (6) via the supply unit (5) (ordirectly to the control unit (6)), assessed and displayed for the userin a form legible to humans. The user may be the patient here, but mayalso be a treating doctor or a technician. The control unit (6) may bedesigned so that the function of the device is guaranteed even if thecontrol unit (6) fails. The control unit (6) may also have purelyinformative functions.

The monitoring unit (7) may also be a control unit (6). However, it mayalso carry out exclusively monitoring functions. It may be connected tothe control unit (6), but also to the supply unit (5) via one of themeans of communication specified above. The monitoring unit (7) may beused in software form on hardware from third-party suppliers and thenuse the communication interfaces thereof. However, as with the controlunit (6), the monitoring unit (7) may also be embodied as a separatepiece of hardware with software played on it. The same functionalitiesmay be carried out in respect of the software of the monitoring unit (7)as in the control unit (6). The monitoring unit (7) may, in particular,assume the function of quickly passing information on to the user. Inthe embodiment shown, the monitoring unit (7) is affixed to the wrist ofthe user and may therefore be viewed quickly. In the event of atechnical or medical emergency, which may be recorded by the supply unit(5) or redundantly by the control unit (6) and/or the monitoring unit(7), this may be communicated to the environment (the user and theirsurroundings) via the monitoring unit (7) and/or the control unit (6).It is possible here to provide both local notifications (of a visual,acoustic or haptic nature) and notifications which may be sent directlyto certain places, for example the emergency doctor or a different thirdplace. This enables the response time to be reduced in the event of anemergency. It is also conceivable, if the control unit (6) is a mobiletelephone, for the emergency doctor to communicate directly with thepatient, a first aider or a doctor on site using this apparatus. Themonitoring unit (7) may also measure at least one parameter of the body,for example the oxygenation of the blood or the person's pulse. Themeasurement of other parameters of the body is also conceivable.

The overall device, consisting of an implant (100) and a supply unit (5)connected thereto, may also be implanted entirely in the body. Energymay be supplied here through electromagnetic induction from outside thebody and so recharge the at least one accumulator or the at least onebattery. An advantage of this embodiment is that it avoids anyartificial body opening (905) that is required to lead the cable harness(4) from the implant (100) to the supply unit (5). The supply unit (5)may be implanted above the liver and the diaphragm in the chest cavityor laterally to the right under the diaphragm in the abdominal cavity.Other implantation sites are also conceivable. If the supply unit (5) isimplanted under the diaphragm, the cable harness (4) may pierce throughthe diaphragm in order to be fed to the pericardium (901).

FIG. 2 shows an embodiment of the implant in the implanted state.Depicted by way of example are a human heart (900), a frame structure(1), a sleeve (2), an expandable unit (21) with the associated line(213), a substance carrier (211), the substance administered thereon(212), sensors and/or electrodes with the associated wires, a fixingsleeve (41), a part of a cable harness (4), a pericardium sluice (3) anda fixing ring (42) of the implant.

The frame structure (1) in this embodiment is depicted as a wireframework. The frame structure (1) may be formed out of at least onewire. The frame structure (1) may also be formed out of two, three,four, five, six or more wires. The frame structure (1) may also be astructure consisting of struts. In this case, the frame structure (1)consists of at least one strut. The frame structure (1) may also beformed out of two, three, four, five, six or more struts. One functionof the frame structure (1) may be to guarantee mechanical stability inthe expanded state. A further function of the frame structure (1) may beto allow expansion from the non-expanded state to an expanded state. Afurther function of the frame structure (1) may be to stretch a sleeve(2) which may be affixed in or on the frame structure (1) in order toform it into a specific shape. The spaces in the frame structure (1)which are defined by the at least one wire or the at least one strut maybe openings in the frame structure (1). They may serve to increaseflexibility, save weight or facilitate the exchanging of liquid fromoutside the frame structure (1) into its internal cavity and vice versa.More detailed explanations of the make-up and details relating to thefunctioning of the frame structure (1) are provided in one of thefollowing sections.

A sleeve (2) may be inserted into the frame structure (1). The sleeve(2) may be affixed to the frame structure (1). The inside or theinternal face is defined as the side or surface of the sleeve (2) facingthe heart in the implanted state of the device. The outside/externalface is the correspondingly opposite side/surface of the sleeve (2). Thesleeve (2) may at least partially following the shape of the surface ofa heart (900) or of a copy of a heart (900). The sleeve (2) may bedesigned to be patient-specific. In the implanted state, the sleeve (2)may at least partially surround part of a heart (900). The sleeve (2)may be affixed to the frame structure (1) such that the sleeve (2) ispulled over the edge of the frame structure (1) at the upper edge of theframe structure (1). In a further step, that part of the sleeve (2) thathas been pulled over is connected to the part that has not been pulledover through openings present in the frame structure (1). The two partsmay be welded, stitched or stuck together. Other methods of coupling,for example positive connections, are also conceivable. The sleeve (2)may also be affixed to the frame structure (1) through hanging frompoints provided for that purpose. At least one sensor and/or at leastone electrode (23) may be mounted both on the inside of the sleeve (2)and on the outside of the sleeve (2). The sleeve (2) may consist ofplastic, polymer, rubber, gum, latex, silicon or polyurethane. Thesleeve (2) may have a thickness of 0.1 mm to 1 mm, preferably 0.2 mm to0.5 mm.

The process for producing the sleeve (2) may be divided into a number ofsubsidiary steps. The starting point for a patient-specifically formedsleeve geometry may be a medical image data record. The patient-specificheart geometry may be extracted therefrom and transferred into athree-dimensional copy. This copy may form a model for the process ofshaping the sleeve (2). In order to shape the sleeve (2), a moulding maybe required which may be derived from the three-dimensional copy of theheart (900). The moulding may be milled from a single piece.Alternatively, it may also be produced using a 3D printing method from athree-dimensional computer model. Alternative manufacturing methods forproducing the moulding, such as casting, are also conceivable. Thesleeve (2) may surround a heart (900) and lie here at a specificdistance from the surface of the heart. The distance may be between 0 mmand 3 mm, or between 0.4 mm and 2 mm. In order to create this spacing,the three-dimensional copy of the heart (900) may be scaled. The scalefactor may be chosen here such that the distance between the surface ofthe heart and the sleeve (2) corresponds to the value range specifiedabove. The moulding may consist of a metal. The moulding may alsoconsist of a plastic. Metallic materials may be aluminium and aluminiumalloys, steel and steel alloys or copper and copper alloys here. Othermetals may also be possible. In the case of an embodiment of themoulding made out of plastic, for example, polyurethane (PU), polyamide(PA) or polyethylene (PE) may be possible. Other plastics havingsuitable mechanical properties may also be possible. The moulding mayalready have characterizations for the position of at least oneexpandable unit (21), which simplifies the subsequent process ofmounting the at least one expandable unit, for example on manualproduction and mounting of the at least one expandable unit. It is alsopossible for places already to be provided on the moulding wheredelivery lines may start, for example for pneumatic actuation of theexpandable units (21) or for delivery of the substance in the substancecarriers (211) described in more detail in a subsequent section. Thesleeve (2) may be stretched over the moulding and becomes plasticallydeformable when the temperature is increased. The sleeve (2) may clingto the moulding and take on the shape of the moulding after cooling. Theinstructions for the positioning of the expandable units (21) and thestarting points of the delivery lines may also be imprinted on thesleeve (2) in this way. Finally, a protrusion of the material of thesleeve (2) over the actual geometry of the sleeve (2) may be used tocouple the sleeve (2) to the frame structure (1), for example by turningit inside out, in a subsequent manufacturing step.

The sleeve (2) may be coupled to the frame structure (1). The couplingmay be carried out at the upper edge of the frame structure (1) (wherethe previously described alternating wire or strut feed is provided), inparticular by turning up the sleeve (2) and by coupling the sleeve (2)to itself through the openings in the frame structure (1). The sleeve(2) may be coupled to itself, for example, through adhesion, welding orstitching. Other methods of connection which achieve the same effect arealso possible. For example, the sleeve (2) may be suspended from pointsprovided on the frame structure (1) for that purpose (for example at theends of the alternating wire feed). In such a case, the sleeve (2) mayhave at least one pocket which may be pulled over at least one loop orat least one stirrup.

The frame structure (1) may have an opening (26) at the lower end. Partof the sleeve (2) may penetrate through this opening (26), for examplebetween 3 mm and 2 cm of the sleeve (2) may penetrate through. Thesleeve (2) may also be open underneath, thereby improving the exchangingof liquid between the space inside the sleeve (2) and the space betweenframe structure (1) and pericardium (901) and vice versa. For example,pericardium liquid may flow in and out through the opening (26) in thesleeve (2). The upper edge of the frame structure (1) preferably runsparallel with the level of the heart valve and may have at least onearea with at least one recess (12). The recess (12) in the framestructure (1) may be necessary owing to anatomical conditions, forexample in order not to spatially impair the inferior vena cava whichruns from the back towards the right atrium of the heart (900). Spatialimpairment of the inferior vena cava would lead to inferior cavasyndrome (obstruction of the filling of the right atrium). A recess (12)may also be necessary on account of other anatomical or cardialstructures. If the frame structure (1) is designed as a lattice or wiremesh, the recess (12) may be made through subsequent detachment ofstruts or wires. Alternatively, a manufacturing method may also bechosen in which the recess (12) does not have to be produced afterwards.For example, in the case of frame structure (1) made out of a wire mesh,the wire winding may be adjusted so that the wires are chosen to beshorter at the site of the recess (12) and the crossing points movecloser together. In the case of a frame structure (1) which consists ofa lattice made out of a slotted tube, the recess (12) may be madethrough suitable cutting of the tube and correspondingly modifiedslotting. The slotting may be adjusted so that, despite the recess (12),the number of cells in the frame structure (1) remains the same. Thismay be necessary for stability reasons. If more flexibility in the framestructure (1) is desired, the slotting of the tube may be modified suchthat one, two or three rows of cells are omitted at the site of therecess (12). The sleeve (2) may be adapted to the recess (12) and mayitself have a recess (25) which coincides as far as possible. Along theupper edge of the frame structure, the recess (12) may have a length of2 cm, 3 cm, 4 cm, 5 cm, 6 cm, 7 cm or more. The depth of the recess(12), measured from the imaginary uninterrupted upper edge of the framestructure to the point of the recess (12) which lies closest to the apexof the heart, may be between 1 mm and 40 mm, in particular between 3 mmand 15 mm. In the circumferential direction, the recess (12) ispositioned where the inferior vena cava opens into the right atrium. Therecess (12) may be curved, semicircular, rectangular or polygonal. Therecess (12) may be sufficiently long that it corresponds to thecircumference of the upper edge of the frame structure (1). The recess(12) may then begin and end at the point of the upper edge of the framestructure (1) which lies opposite the cardial structure to be left free,for example the inferior vena cava. This may result in the recess (12)defining a level which is tipped over with respect to the level of theheart valve and which comes to rest at the site to be left free 1 mm to40 mm, in particular 3 mm to 15 mm lower than if the upper edge of theframe structure (1) were to run parallel to the level of the heartvalve. The sleeve (2) has a recess (25) which essentially corresponds tothe recess (12) in the frame structure (1) in terms of its shape,position and dimensions and which leaves free the anatomical area aroundthe inferior vena cava. Spatial impairment of the inferior vena cavathrough the sleeve (2) and the resultant obstruction of the filling ofthe right atrium is thereby prevented. The recesses (12, 25) in thesleeve (2) and frame structure (1) may be made to coincide with oneanother.

The frame structure (1) may have several markings As already described,these markings may be in various forms or positions. In the presentembodiment, the markings may be made on the upper edge and at the lowerend in the direction of the apex of the frame structure (1).

At the lower end of the frame structure (1), one, two, three, four,five, six or more extension struts (11) may be mounted on the framestructure (1). The extension struts (11) represent an extension of theframe structure (1) in the direction of the longitudinal axis of theheart. The extension struts (11) may run in the direction of animaginary apex of the heart, rest there or not rest and protrude fromthere away from the heart (900) in the direction of the longitudinalaxis of the heart. The extension struts (11) may be gathered together ina joint fixing sleeve (41). The extension struts (11) and/or the fixingsleeve (41) may be connected to the cable harness (4) of the device, forexample by gluing, welding or positive or non-positive anchoring. Theextension struts (11) may serve to fix the frame structure (1) in theaxial direction. The extension struts (11) only partially restrict therotation of the frame structure (1) about the longitudinal axis of theheart. If the frame structure (1) is made out of a wire mesh, theextension struts (11) may represent the extended ends of wires. Theextension struts (11) and the wire mesh may therefore be one part. Ifthe frame structure (1) consists of a lattice that has been made out ofa slotted tube, the lattice may be made using the extension struts (11)through suitable cutting out of just one tube. The lattice and theextension struts (11) may therefore be one part. The extension struts(11) and the frame structure (1) may also be multi-part, whereby theextension struts (11), after production of the frame structure (1), areaffixed thereto, for example through a suspension mechanism or throughmaterial bonding (welding, gluing). Alternative methods of couplinghaving the same or similar effect are also conceivable. The length ofthe extension struts (11) may be between 1 cm and 10 cm, in particularbetween 4 cm and 7 cm.

The frame structure (1) may comprise only the recess (12) describedabove and no extension struts (11). Alternatively, the frame structure(1) may comprise both the recess (12) described above and the extensionstruts (11) described above. The frame structure (1) may also compriseonly the extension struts (11) described above and no recess (12).

At the lower end of the frame structure (1) there may be at least oneextension strut (11) which fixes the frame structure (1) to the cableharness (4) in the axial direction and stabilizes the device. The atleast one extension strut (11) may be coupled to the cable harness (4)of the device. Possible methods of coupling are sticking, clamping,moulding, plug connection, suspension or welding. Alternative methods ofcoupling are also conceivable. Part of the at least one extension strut(11) may also remain in a fixing sleeve (41) after implantation.

The implant (100) may also comprise a fixing sleeve (41). The fixingsleeve (41) is represented in the present embodiment as a hollowcylinder through which pneumatic/hydraulic, electrical and substancelines may be fed from the distal end of the fixing sleeve (41) andbunched together in the cable harness (4) at the proximal end of thefixing sleeve (41). The cable harness (4) may be coupled to the fixingsleeve (41), for example by means of an adhesive connection (materialbonding) or non-positive connection (for example by shrinking the cableharness sheath onto the fixing sleeve (41)). Other methods of couplingare also conceivable.

The fixing sleeve (41) and the cable harness (4) may alternatively alsobe coupled via an intermediate piece. This intermediate piece may, forexample, consist of at least one segment which may allow an at leastpartially rotatory and/or at least partially translational relativemovement between the cable harness (4) and the fixing sleeve (41). Theadvantage of such indirect coupling is the virtually independentsettability of the orientation of the longitudinal axis of the framestructure (1) and of the fixing sleeve (41) and of the orientation ofthe cable harness (4). The intermediate piece may, for example, bedesigned as a ball joint. The intermediate piece may alternativelyconsist of a hose construction comprising at least one segment. As thematerial of the intermediate piece, polymers, plastics or metals andmetal alloys may be used. Other materials which meet the mechanicalrequirements (in particular with regard to fatigue strength) may also beused.

A fixing ring (42) interacting with the fixing sleeve (41) may also beused to seal the pericardium (901). Together with the fixing sleeve(41), the sluice and a fixing ring (42), the at least one axialextension strut (11) may form the device for closing the pericardium(901). The fixing ring (42) may, for example for stiffening purposes,have a core (421) consisting of a stiffer material than the rest of thefixing ring (42). Possible materials may be steel, nitinol or a stiffpolymer. Other materials are also conceivable. If alternative devicesare used to seal the pericardium (901), for example through use of amulti-part pericardium sluice (3), at least part of the at least oneextension strut (11) may also lie outside the pericardium (901) and atleast part of the at least one extension strut may lie inside thepericardial cavity (902). If the device should have a force exerted onit away from the heart (900) in the direction of the longitudinal axisof the heart as a result of the expansion of the at least one expandableunit (21), some of this force may be dissipated via the frame structure(1), the extension struts and the cable harness (4) without anyresultant dislocation of the device. The extension struts (11) may have,at their ends, holes, stirrups, loops or angled ends which facilitatethe minimally invasive explantation of the frame structure (1) and thesleeve (2). The angled ends, holes, stirrups or loops do not impede thefixing of the extension struts (11) in the fixing sleeve (41). They maybe used for fixing or centring the extension struts (11) in the fixingsleeve (41). Upon implantation or during operation of the device, endsof the extension struts (11) may be located inside the cable harness (4)or inside the fixing sleeve (41). Implantation and explantation of theimplant are described in more detail in following sections.

At least one expandable unit (21), for example in the form of abellows-like chamber, may be mounted on the sleeve (2). The expandableunit (21) may be an actively expandable unit (21) or a passivelyexpandable unit (21). A sensor and/or an electrode (23) may also bemounted on the sleeve (2). The sleeve (2) may be the underside of theexpandable units (21). The expandable units (21) may be adjusted to theshape of the heart (900), the frame structure (1) and/or the sleeve (2).One, two, three, four, five, six, seven or more expandable units (21)may be mounted on the sleeve (2). When expanding, the expandable units(21) may exert a pressure on the heart muscle. This pressure ispreferably exerted in areas of the heart muscle under which a heartchamber is located, preferably below the level of the heart valve. Inanother embodiment, the pressure may also be exerted above the level ofthe heart valve in the case of certain therapeutic uses. If theexpandable units (21) are positioned in the lower area of the sleeve (2)and/or frame structure (1) near the apex of the heart, on expansion ofthe expandable units (21), the heart muscle is pressed in the directionof the longitudinal axis of the heart upwards to the level of the heartvalve. If the expandable units (21) are arranged in the upper area ofthe sleeve (2) and the frame structure (1), on expansion of theexpandable units (21), the heart muscle is pressed perpendicularly tothe longitudinal axis of the heart. Pressure is then exerted on theheart muscle parallel to the level of the heart valve (laterally ontothe ventricle). The expandable units (21) may also be positioned in anyposition between the lower edge and the upper edge of the sleeve (2) andframe structure (1), whereby the pressure of the expandable units (21)when they expand acts partly in the direction of the longitudinal axisof the heart and partly parallel to the level of the heart valve. Onexpansion of the expandable units (21), the pressure therefore acts asfar as possible parallel to the level of the heart valve. Thecounterforce on the device in the direction of the longitudinal axis ofthe heart is therefore kept at a low level. Displacement of the deviceaway from the heart in the direction of the longitudinal axis of theheart (dislocation) caused by expansion of the expandable units (21) istherefore minimized. The self-expanding frame structure (1) and thesleeve (2) have recesses (12, 25) in this depiction in order not tospatially impair the inferior vena cava in the implanted state of thedevice. The expandable units (21) may be adjusted in terms of theirsize, shape and position to the recesses (12, 25) in the frame structure(1) and the sleeve (2) so that they do not cover the recesses (12, 25)either in the expanded or in the non-expanded state.

The at least one expandable unit (21) may carry out various tasks. Itmay exert a temporally adjustable pressure on the surface of the heartwhich is preferably periodic or dependent on the current phase of theheart cycle. If the aim of exerting pressure is to increase the emissionof blood, the expandable unit (21) may be an augmentation unit. Theconcept of augmentation may therefore be understood to refer to thesupportive increase or at least the changing of a heart parameter suchas the emission quantity. Alternatively, the at least one expandableunit (21) may also exert temporally variable pressure on the surface ofthe heart without the primary aim thereof being to increase the quantityof blood emitted. Instead, this kind may relate to an expandable unit(21) serving to position or stabilize the implant with respect to theheart (900). In both said cases, energy needs to be supplied in order tobe able to set the degree of expansion of the at least one expandableunit (21). These may be active expandable units (21). Alternatively, theat least one expandable unit (21) may also manage without a supply ofenergy. In this case, the at least one expandable unit (21) may have apreviously settable degree of expansion and keep this irrespective oftime. Such an expandable unit (21) may be regarded as a passiveexpandable unit (21). This kind of expandable unit (21) is described inmore detail in a subsequent section.

The expandable unit (21) may be a mechanical unit which may have anexpanded and a non-expanded configuration. The at least one expandableunit (21) may also have configurations between the expanded and thenon-expanded configuration. The at least one expandable unit (21) mayserve to exert pressure on the surface of the heart. The at least oneexpandable unit (21) may serve to position a substance (212) or asubstance carrier (211). The at least one expandable unit (21) may alsoserve to ensure contact between the surface of the heart and a substancecarrier (211) or a substance (212) which is located on the surface ofthe expandable unit (21). The expandable unit (21) may also serve toproduce a defined state of mechanical load in the substance (212) and/orin the substance carrier (211).

The at least one expandable unit (21) may consist of the same materialas the sleeve (2). The material of the at least one expandable unit (21)may also differ from the material of the sleeve (2). The material of theat least one expandable unit (21) may be a polymer. The material of theat least one expandable unit (21) may be polyurethane, silicone orpolytetrafluoroethylene (PTFE). Other materials which are in principleable to meet the requirements of an expandable unit (21) are alsoconceivable. The at least one expandable unit (21) may be designed as aninflatable, bellows-like chamber. The chamber provided in the depictedembodiment is in the form of a set of bellows. A bellows-like chamberhas at least one section in the form of a set of bellows. The expandableunit (21) may be a set of bellows that consists of one, two, three,four, five, six, seven or more pleats. The at least one expandable unit(21) may also differ from the form of a set of bellows.

Such an expandable unit (21) may be operated through tensionable andreleasable spring elements, foldable and unfoldable lever elementsand/or an elastic, sponge-like or foam-like internal structure. Theexpandable unit (21) may also be actuated electrically, for examplethrough at least one electromagnet. The at least one electromagnet maybe affixed to one side of the expandable unit (21) or incorporated intoa wall of the expandable unit (21). A ferromagnetic, paramagneticmaterial, for example in the form of wires, a thin plate or foil, or afurther electromagnet may be placed on the surface of an expandable unit(21) positioned opposite so that energization of the at least oneelectromagnet causes a change in the state of expansion of theexpandable unit (21). Alternatively, spring elements, lever elements,electromagnets and/or ferromagnetic materials may be combined with oneanother in an expandable unit (21). For example, the expandable unit(21) may be expanded through one or more spring elements andenergization of the at least one electromagnet may lead to the mutualattraction of the sides lying opposite one another and hence to thereturn to a non-expanded state. The at least one expandable unit (21)may have a delivery line for supplying energy which is required tochange the expansion state. If the expandable unit (21) is operatedelectrically, for example electromagnetically, the line (213) forsupplying energy may be an electric cable.

Alternatively, the at least one expandable unit (21) is a chamber whichmay be filled with a fluid. As fluids which are suitable for filling thechamber, liquids, gases, solids (for example nanoparticle mixtures) ormixtures of liquids and/or gases and/or solids are possible. In thiscase, the expandable unit (21) has a delivery line through which themedium used to expand the at least one expandable unit (21) may be fed.The at least one expandable unit (21) may have a discharge line throughwhich the medium used to expand the at least one expandable unit (21)may be discharged. A line (213) may also be provided for delivering anddischarging the medium used for expanding the at least one expandableunit (21).

The at least one expandable unit (21) may be affixed to the inside ofthe sleeve (2). The expandable unit (21) may also be affixed to theoutside sleeve (2). The at least one expandable unit (21) may be mountedin any desired area of the outside or inside of the sleeve (2).

The area of the surface of the heart which may require the use of the atleast one expandable unit (21) may be in a different place depending onthe individual patient concerned. The free positionability of the atleast one expandable unit (21) serves to adapt the implant to theindividual geometry of the heart to be treated.

The at least one expandable unit (21) may be in the form of a chamber.The chamber may be bellows-like. A bellows-like chamber has at least onesection in the form of a set of bellows. A pleat may be defined as anoutwardly directed fold line. A pleat may be defined as an inwardlydirected fold line. One, a number or all of the fold lines may bestrengthened. Strengthening of a fold line is advantageous because thefold line may be exposed to increased loads as a result of the expandingand contracting of the chamber. Strengthening one or more fold lines mayreduce or prevent material fatigue along the at least one fold line.Strengthening of a fold line may be achieved through a greater wallthickness of the material at the fold line. A fold line may also bestrengthened by applying additional material, wherein the appliedmaterial may be the same material as the material underneath or whereinthe applied material may be a different material from the materialunderneath. A chamber may have a top, an underside and a side surface,wherein the side surface is preferably designed in the form of a set ofbellows. The top and/or underside may be oval, circular, elliptical orpolygonal. The top may be a different shape than the underside.

A bellows-like chamber may be provided in a frame structure (1) asdescribed above. The chamber may be affixed or attached directly in theframe structure (1). The chamber may be affixed to structural elementsof the frame structure (1), such as a wire of a wire mesh, a strut of alattice or a structure on a frame structure sheath. The chamber may beaffixed to crossing points of a mesh or lattice.

The bellows-like chamber may also be affixed to the sleeve (2). Aplurality of bellows-like chambers may be affixed to the sleeve (2). Thesleeve (2) may be at least partly in the shape of a heart (900). Thesleeve (2) may have a shape similar to the frame structure (1). Thesleeve (2) may, in addition to one or more augmentation units, such asone or more bellows-like chambers, also have one or more positioningunits. The underside of the chamber may be made out of the same materialas the sleeve (2). The sleeve (2) may be part of the chamber. The sleeve(2) may form the underside of the chamber. In such cases, only the sidesurfaces which may be bellows-like are mounted on the sleeve (2). A topmay also be provided. The top may also be a sleeve (2), but may also bea top embodied as a separate component. The at least one line (213)which supplies the at least one expandable unit (21) may be defined,like the chamber, at least partly also using the sleeve (2) as the backand a front provided, for example, through adhesive or weldedconnection. The at least one line (213) may alternatively also be acompletely separate, hose-like component.

The at least one expandable unit (21) may have at least one sensorand/or at least one electrode (23). This sensor may preferably bemounted on a surface of the at least one expandable unit (21) facing theheart (900). However, the sensor may also be mounted somewhere else onthe at least one expandable unit (21). The sensor may be a temperaturesensor, a pressure sensor, a pH sensor, an oxygen sensor, a CO₂ sensor,an optical sensor or a conductivity sensor. Alternatively, the at leastone sensor may also serve as an impedance sensor for monitoring theadhesion of cells or cell cultures applied to the at least oneexpandable unit (21) or for monitoring contact with the epicardium. Theelectrode (23) may also be a sensor. The advantage of providing the atleast one sensor and/or the at least one electrode (23) is that, withthe aid of the at least one expandable unit (21), constant contact ofthe at least one sensor and/or the at least one electrode (23) with thesurface of the heart may be guaranteed.

The position and/or shape of the at least one expandable unit (21) maybe described in the form of coordinates in three-dimensional, Euclideanspace so that these coordinates correspond to points on the surface ofthe sleeve (2) and may therefore be interpreted and used, for example,by machine tools such as milling machines, 3D printers, industrialadhesion robots or laser cutting machines. These coordinates may bedetermined using the three-dimensional image data of the heart (900),for example from a CT data set. For example, the position and/or shapeof the at least one expandable unit (21) may therefore be adjusted tothe position and/or shape of an anatomical structure or the positionand/or shape of a pathological change in the heart (900), for examplecaused by a myocardial infarction. The at least one expandable unit (21)may at least partially cover the site of a myocardial infarction or maybe positioned in the immediate spatial vicinity of the site of theinfarction (the “border zone”).

The sleeve (2) may comprise at least one sensor and/or at least oneelectrode (23) for measuring a parameter of the heart (900) or forstimulating the heart (900). A more detailed explanation is provided ina subsequent section. The at least one electrode (23) may be made out ofnitinol which increases its deformability and may therefore beadvantageous for the minimally invasive insertion of the implant in thenon-expanded configuration. Other common electrode materials are alsoconceivable. For example, the electrode (23) may also have a coating toimprove its electrical properties which may be advantageous, inparticular, when measuring at least one parameter of the heart (900).

At least one substance carrier (211) may be inserted into the sleeve(2). The at least one substance carrier (211) serves to store at leastone substance (212) which may have at least one therapeutic effect. Thesubstance (212) may be provided as a liquid, gel, in paste form, as asolid or in a combination thereof, for example as an emulsion orsuspension. The substance (212) may partly consist of a liquid and/or asolid and/or animal or human cells and/or proteins and/or a gas. The atleast one therapeutic effect of the substance (212) may beantithrombotic, antiproliferative, anti-inflammatory, antineoplastic,antimitotic, antimicrobial, anticoagulant, cholesterol-lowering or acombination thereof. The substance (212) may contain a biofilm synthesisinhibitor, an antibiotic, an antibody, a beta blocker or combinationsthereof. The substance (212) may contain living biological cells. Thesubstance (212) may contain proteins and/or active agents which enableliving biological cells to survive and/or may influence cell activityand hence therapeutic efficiency. The proteins and/or chemicals may beencapsulated in micro- and/or nanoparticles which allow the encapsulatedproteins and/or chemicals with defined release kinetics for targetedrelease of proteins and/or chemicals. The at least one substance carrier(211) may be positioned and affixed on an expandable unit (21). The atleast one substance carrier (211) may also be positioned and affixeddirectly on the sleeve (2). The area of positioning of the at least onesubstance carrier (211) either on the at least one expandable unit (21)or the surface of the sleeve (2) is entirely optional. The free choiceof location in which to position the at least one substance carrier(211) enables the patient-specific adjustment of the implant. Theposition and shape of the substance carrier (211) may be based, forexample, on the site of any heart disease, for example a myocardialinfarction. The substance carrier (211) may at least partially cover thesite of a myocardial infarction or may be positioned in the immediatespatial vicinity of the site of the infarction (the “border zone”). Theadvantage of positioning the at least one substance carrier (211) in theborder zone may be that this region has living tissue. In the case of asubstance (212) which adheres well to the sleeve (2) or the expandableunits (21), direct application in the form of a spread or a coating mayalso be considered, rendering the substance carrier (211) unnecessary inthis embodiment. The border zone may, for example, be premarked oroutlined on the sleeve (2) (if applicable with a certain tolerance) sothat the substance (212) may be applied in a targeted manner in thislocation. This may prevent administration in the wrong place. Thesubstance carrier (211) in the present embodiment is represented as afoil-like component affixed to the at least one expandable unit (21).The substance carrier (211) may be flat in shape. The substance carrier(211) may have a thickness of between 0.01 mm and 5 mm, between 0.05 mmand 2 mm, and preferably between 0.2 mm and 1.5 mm. That surface of thesubstance carrier (211) facing the heart (900)—the end face of thesubstance carrier (211)—may be at least partially circular, elliptical,rectangular or polygonal. The at least one substance carrier (211) maybe patient-specific (with respect to geometry and therapeutic effect,for example in the dosage of the at least one active agent) and may beadjusted, for example, in terms of its size, taking account ofanatomical features or the size and structure of a pathological changein the heart tissue or the shape of the at least one expandable unit towhich the substance carrier (211) may be affixed. The fixing of the atleast one substance carrier (211) to the at least one expandable unit(21) or the sleeve (2) is carried out through positive coupling,non-positive coupling and/or material bonding. In the case of positiveconnection, the coupling may be carried out through hooks, eyelets,buttons, loops or at least one Velcro fastening and/or zip. At least onehook and at least one eyelet, at least one hook and at least one loop,at least one button and at least one complementary positive lockingelement or at least one hook and at least one further hook may be theconnection partners here. In the case of a non-positive connection, theat least one substance carrier (211) may be connected in a frictionallyengaged manner by means of filamentary or lamellar extensions tolikewise filamentary or lamellar extensions on the at least oneexpandable unit (21) or the sleeve (2). In the case of a materiallybonded connection, the connection between the at least one substancecarrier (211) and the at least one expandable element or the sleeve (2)may be carried out by gluing, vulcanization or welding. In the presentembodiment, the substance (212) may be a gel or a paste and may beapplied to the end face of the substance carrier (211). The substance(212) may be applied to the end face of the substance carrier (211) bygluing, spreading, brushing or spraying. Other methods of applicationare also conceivable.

The substance carrier (211) may also differ from the flat shape. Thesubstance carrier (211) may be designed as a container, or else as apouch or pocket. The substance carrier (211), in its embodiment as apouch or pocket, may receive, hold and release the substance (212) to beadministered. The substance (212) may be inserted into the substancecarrier (211) and removed again in the implanted state. It may also beinserted into the substance carrier (211) in the non-implanted state andmay remain in the substance carrier (211) or be removed again any timeup until explantation of the implant. A more detailed description isprovided in a subsequent section.

The sleeve (2) may also comprise at least one sensor and/or at least oneelectrode (23) with the aid of which at least one parameter of the heart(900) may be detected, for example the heart rate, the ventricularpressure, the contact force between the wall of the heart and anexpandable unit, the systolic blood pressure or the diastolic bloodpressure. The at least one sensor may also serve to determine variousparameters in the substance carrier (211) and/or the surroundings of thesubstance carrier (211). The at least one sensor may be a temperaturesensor, a sensor for detecting mechanical forces acting on the substancecarrier (211) or a sensor for determining the concentration ofsubstances influencing the conductivity, substances influencing the pHvalue, and substances influencing the oxygen and CO₂ content in thesubstance carrier (211) and/or the surroundings of the substance carrier(211). The at least one sensor may also be able to measure the pressureexerted by an expandable unit (21) on a surface, the pH value, theoxygenation, the electrical resistance, the osmolarity of a solution orthe flow rate through a vessel. The at least one sensor may be mountedin, at or on the frame structure (1). The at least one sensor ispreferably affixed to the sleeve (2) which may be inserted into theframe structure (1). The at least one sensor may also be an electrode(23).

The cables (221) may be designed as conducting paths. The conductingpaths of the at least one sensor and/or of the at least one electrode(23) may be mounted at least partially on the sleeve (2). For example,the conducting paths may be mounted on foils of polyimide (PI), forexample through vapour deposition or sputtering. Other methods ofmounting or removal which allow conducting paths to be formed are alsoconceivable. Alternatively, conductive sensor cables and/or electrodecables or sensor conducting paths and/or electrode conducting paths maybe glued onto the sleeve (2) or welded in it. The conducting paths mayconsist at least partially of nitinol here. The at least one electrode(23) may consist of the same material as the conducting paths. Asanother alternative, the conducting paths and/or the at least oneelectrode (23) may also consist of conductive electrographic ink and beprinted onto the sleeve (2). Alternatively, the conducting paths of theat least one sensor and/or the at least one electrode (23) may also befed without coupling to the sleeve (2) inside or outside the sleeve (2)in the direction of the fixing sleeve (41) and cable harness (4).

The at least one electrode (23) may be able to stimulate areas of theheart (900) and/or measure the potential for action in the heart muscleduring the stimulation process. In particular, the at least oneelectrode (23) may be able to stimulate the heart muscle with the aid ofelectrical impulses. Electrical stimulation may incite a heart muscle tocontract. The at least one electrode (23) may be a pacemaker electrode.The electrode (23) may be an extracardial stimulation electrode. Theheart muscle may be stimulated with an electrode (23) before, during orafter any support of the pumping function of the heart (900) by a framestructure (1) with at least one expandable unit (21). The at least oneelectrode (23) may also carry out a defibrillation function. The atleast one electrode (23) may be in the form here of a flat, conductivepatch which may be located at points on the surface of the heart whichare suitable for defibrillation. An advantage of a patch may be the flatstructure of an electrical field, the field lines of which are designedto be straighter than in rod-like or punctiform electrode geometries.Alternatively, the frame structure (1) may also function as an electrode(23). In this case, at least one further electrode (23) must beprovided. The expansion of an expandable unit (21) may take placebefore, during or after any stimulation with an electrode (23). Thedevice for supporting the functioning of a heart (900) may only beoperated with at least one expandable unit (21) or only throughstimulation with at least one electrode (23). Simultaneous operation ofthe at least one expandable unit (21) and the at least one electrode(23) may be synchronous or asynchronous. The at least one electrode (23)may also be used as a sensor. The at least one sensor and/or the atleast one electrode (23) may comprise at least one electric cable (221).The at least one cable (221) may be incorporated into the sleeve (2).The at least one cable (221) may also be a conducting path insulatedfrom the surroundings. The electrically conductive material may bemounted on the sleeve (2) and also insulated. The at least one cable(221) may be coupled to the sleeve (2), welded into the sleeve (2) orstuck to the sleeve (2). Depending on the position of the at least onesensor and/or the at least one electrode (23), the at least one cable(221) may run on the outside or the inside of the sleeve (2). The atleast one cable (221) may also be fed through an opening (26) providedin the sleeve (2) for that purpose and fed along on the outside in thecase of at least one sensor and/or at least one electrode (23) lying onthe inside of the sleeve (2). The at least one cable may also be fedthrough an opening (26) provided in the sleeve (2) for that purpose andfed along on the inside in the case of at least one sensor and/or atleast one electrode (23) lying on the outside of the sleeve (2).

The sleeve (2) may have an opening (26) at the lower end. This opening(26) may serve to feed out from inside the sleeve (2) the extended endsof the at least one wire or of the at least one strut in the case of anembodiment in which the frame structure (1) lies inside the sleeve (2).This opening (26) may serve to feed the at least one line (213) of theat least one expandable unit (21), in the case of an embodiment in whichthe at least one expandable unit (21) is affixed on the inside of thesleeve (2), outwards from inside the sleeve (2). This opening (26) mayserve to feed the at least one cable (221) of the at least one sensorand/or of the at least one electrode (23) from inside the sleeve (2) inthe direction of the fixing sleeve (41) onto the outside of the sleeve(2). This opening (26) may serve to facilitate the exchanging ofsubstances (212) between the outside and the inside of the sleeve (2).

The frame structure (1) may have at least one radiopaque marking (24)with the aid of which the positioning and orientation of the framestructure (1) in relation to a heart (900) may be checked during andafter implantation. Alternatively, the at least one radiopaque marking(24) may serve to set and monitor the desired position of the framestructure (1) which is favourable for implantation in the state insertedinto a delivery system. Detailed explanations regarding the deliverysystem are provided in another section.

FIG. 2 also shows a pericardium sluice (3) which allows the implant tobe inserted into the pericardium (901). The pericardium sluice (3)produces a feed channel for the implant (100) by delimiting a lumen fromthe surrounding tissue. The pericardium (901) is a sac made out ofconjunctive tissue which surrounds the heart (900) and allows the heart(900) free movement through a narrow sliding layer. In the pericardialcavity (902) there is serous fluid, which is also referred to as liquorpericardii. In order that this liquor pericardii cannot flow out througha surgical opening (903) in the pericardium (901) made duringimplantation of the implant and so that no other liquids or solids (suchas cells, proteins, foreign bodies, etc.) can gain access to thepericardial cavity (902), a pericardium sluice (3) may be inserted atleast partially through the surgically made opening (903) in thepericardium (901). The pericardium sluice (3) may close and seal thesurgical opening (903) made in the pericardium (901) for insertion ofthe implant into the pericardial cavity (902). The pericardium sluice(3) may have an internal lumen through which parts of the deviceaccording to the invention may protrude. After the device has beenimplanted, for example, a fixing sleeve (41) or part of the cableharness (4) may be located in the pericardium sluice (3) and remainthere for the duration of the implantation. The pericardium sluice (3)seals the surgical opening (903) made in the pericardium (901) for thecable harness (4). The pericardium sluice (3) may be designed as asingle part. The pericardium sluice (3) may also be designed as twoparts or as multi-part. The pericardium sluice (3) may be rotationallysymmetrical in shape. The pericardium sluice (3) may also be ofasymmetrical shape. The pericardium sluice (3) may be located at leastpartially inside the pericardial cavity (902). The pericardium sluice(3) may be located at least partially outside the pericardium (901).

The pericardium sluice (3) may consist of a single material. Thepericardium sluice (3) may also consist of at least two materials. Thematerial of the pericardium sluice (3) may be at least one polymer. Thepericardium sluice (3) may consist of plastic, polymer, rubber, gum,latex, silicone, polyurethane (PU) or polytetrafluoroethylene (PTFE).The pericardium sluice (3) may consist at least partially of a metal ora metal alloy. The pericardium sluice (3) may consist at least partiallyof a shape memory alloy. The pericardium sluice (3) may consist at leastpartially of nitinol. The pericardium sluice (3) may consist of acombination of at least two of said materials.

An embodiment of the pericardium sluice (3) is shown in cross section inFIG. 2. The embodiment is in two parts. It comprises the device forproducing the lumen and a sealing ring outside the pericardium (901).The pericardium sluice (3) may comprise at least two components, but mayalso consist solely of the device for producing the lumen. Thepericardium sluice (3) in this embodiment has two different ends. Oneend of the pericardium sluice (3) has a sealing lip (31) which may beannular. The other end of the pericardium sluice (3) has no sealing lip(31) in this embodiment. Alternatively, the pericardium sluice (3) mayalso have a sealing lip (31) at both ends. The material of the sealinglip (31) may be the same as the material of the rest of the pericardiumsluice (3). The material of the sealing lip (31) may be different fromthe material of the rest of the pericardium sluice (3). The material ofthe sealing lip (31) may be plastic, polymer, rubber, gum, latex,silicone, polyurethane (PU) or polytetrafluoroethylene (PTFE). Thesealing lip (31) of the pericardium sluice (3) may consist at leastpartially of a metal or a metal alloy. The sealing lip (31) of thepericardium sluice (3) may consist at least partially of a shape memoryalloy. In addition to the sealing effect, the sealing lip (31) may alsohave a mechanically stabilizing effect in the radial and circumferentialdirections. Stiffness in the radial and circumferential directions maybe set through the thickness of the sealing lip (31). The thickness ofthe sealing lip (31) may be between 1 mm and 10 mm. The thickness of thesealing lip (31) may be between 3 mm and 6 mm. The sealing lip (31) mayhave a self-retaining effect. In its implanted form, the upper end ofthe pericardium sluice (3) may be supported with the sealing lip (31)against the inside wall of the pericardium (901). Through the taperingof the pericardium (901) towards the apex of the heart, a mechanicalself-retention may occur between the pericardium sluice (3) and thepericardium (901) and increase the sealing effect and the mechanicalstability and positional accuracy of the pericardium sluice (3).

The core of the sealing lip (31) may be made out of a different materialto the sheathing placed around the core of the sealing lip (31). Atleast one part of the core of the sealing lip (31) may be formed out ofspring steel or a shape memory alloy and the sheathing of the core maybe made out of a polymer. In the case of an embodiment of a pericardiumsluice (3) having a core of the sealing lip (31) made out of metal or ametal alloy, the material of the sheathing of the core of the sealinglip (31) may differ from the material of the core of the sealing lip(31). In the present embodiment of the implant, the device for producingthe lumen consists of one material, preferably of a polymer. The endwith the sealing lip (31) is located inside the pericardial cavity (902)in this embodiment. It is in contact with the inside wall of thepericardium (901) there. The sealing lip (31) guarantees the sealingeffect and stops liquid getting out of the pericardium (901) orsubstances entering the pericardial cavity (902). The self-expandingimplant (100) may be inserted into the pericardial cavity (902) throughthe pericardium sluice (3). As a result, that end of the cable harness(4) with the fixing sleeve (41) which is near the frame structure (1) islocated in the pericardium sluice (3). A sealing connection may be madebetween the fixing sleeve (41) and the pericardium sluice (3). In thepresent embodiment, the sealing effect is produced through a sealingring pulled over the pericardium sluice (3). The seal between thepericardium sluice (3) and the fixing sleeve (41) may also be madepossible by other means. The sealing effect may alternatively beproduced by stitching the pericardium sluice (3) to the fixing sleeve(41), clamping the pericardium sluice (3) by means of a clamp, a clip orby means of at least one cable tie, which may be positioned around thefixing sleeve (41) and the pericardium sluice (3) lying opposite. Thesealing effect may also be produced through the pericardium sluice (3)alone or through part of an embodiment of the pericardium sluice (3).The sealing effect may in this case be produced by suturing, knottingtogether or welding the lower end of the pericardium sluice (3). Thefull sealing of the surgical opening (903) made in the pericardium (901)may be provided at at least two interfaces: between pericardium (901)and pericardium sluice (3) and between pericardium sluice (3) andsurroundings or pericardium sluice (3) and fixing sleeve (41).Additionally, the pericardium sluice (3) can also facilitateexplantation because it effectively reduces the surface area between theimplant and the pericardium (901), thus reducing adhesions between them.

FIG. 2 shows the pericardium sluice (3) in its configuration afterinsertion of the implant into the pericardial cavity (902). The processof inserting the pericardium sluice (3) is explained in more detail in asubsequent section.

An alternative embodiment of the implant may also be designed withoutthe frame structure (1). This may be the case if no mechanicalaugmentation of the myocardium is required. Alternatively, the implant(100) may be designed without the sleeve (2) but with a frame structure(1). This may be advantageous if the mechanical supporting effect of theframe structure (1) is primarily intended to be used.

Other alternative embodiments may consist exclusively of the framestructure (1) and/or the sleeve (2) and at least one expandable unit(21). Such embodiments may therefore be implantable in their entirety.This has the advantage that the risk of inflammation is reduced becauseno cable harness (4) exits from inside the body. The at least oneexpandable unit (21) may, for example with the aid of at least onespring element, set or maintain a certain degree of expansion, whereby,for example, permanent contact of a substance carrier (211) mounted onthe at least one expandable unit (21) with the surface of the heart maybe guaranteed. The spring element may consist of polymer or plastic,metal or metal alloys or a shape memory material. In the case ofembodiments which have no spring element, the expandable unit (21) mayalso be operated pneumatically/hydraulically. For example, a constant ora temporally variable degree of expansion may be set. Instead of atleast one expandable unit (21), a passive silicone patch may also beused. The implant (100) may be designed to be self-sufficient andwithout any energy supply from outside the body. Alternatively, theimplant (100) may also be connectionless, for example supplied withenergy through induction.

A further embodiment may consist solely of at least one sleeve (2),which may be provided with a therapeutic substance (212). Such anembodiment may be implanted in a very space-saving manner. An advantageof such an embodiment may be that it manages without a cable harness (4)or pericardium sluice (3).

FIG. 3 shows a section through a heart (900) around which is placed anembodiment of the implant (100) which is in turn surrounded by thepericardium (901). In the wall of the heart, infarction tissue (904) isschematically distinguished from intact tissue of the heart (900). Anexpandable unit (21) may be positioned such that it completely covers alimited part of the surface of the heart (900) which lies directly abovethe infarction area. The expandable unit (21) is shown in this exemplaryembodiment as an inflatable, bellows-like chamber. The expandable unit(21) may also differ from the form of a set of bellows. The underside ofthe expandable unit (21) is formed from part of the sleeve (2) in thisembodiment. The underside of the expandable unit (21) may also bedesigned separately and then affixed to the sleeve (2), for examplethrough gluing, welding or vulcanisation. With the aid of the expandableunit (21), the substance carrier (211) may be brought into contact withthe surface of the heart. The substance carrier (211) is represented inthis embodiment as a pocket with an opening on the end face. The openingon the end face allows the substance to pass from the substance carrier(211) to the surface of the heart. The underside of the substancecarrier (211) is part of the end face of the expandable unit (21) inthis embodiment. The underside of the substance carrier (211) may alsobe designed separately and affixed to the end face of the expandableunit (21), for example by gluing, welding or vulcanization oralternatively by suspension or with the aid of Velcro fastenings.

In general, the substance carrier (211) may be positioned in any desiredlocation on the surface of the sleeve (2), of the at least oneexpandable unit (21) or of the frame structure (21). In someembodiments, the substance carrier (211) may be positioned at leastpartially on at least one expandable unit (21). The surface covered bythe substance carrier (211) may be identical to and coincident with theend face of the expandable unit (21) here. However, the surface coveredby the substance carrier (211) may also be larger or smaller than theend face of the expandable unit (21). The surface covered by thesubstance carrier (211) may be influenced by the size of the area to betreated on the surface of the heart. In embodiments with substancecarriers (211) which take up a larger surface area than the at least oneexpandable unit (21) covered thereby, the mechanical load introducedinto the substance carrier (211) through expansion of the expandableunit (21) may have a therapeutic effect. A more detailed description ofthis point is provided in a subsequent section. If the contact betweensubstance (212) or substance carrier (211) and the surface of the heartis not permanent, that is to say in some embodiments it is preferablycontrollable or at least settable, the substance carrier (211) may alsobe positioned in areas of the implant (100) in which there is nooverlapping of the substance carrier (211) and at least one expandableunit (21).

Alternatively, an embodiment is also conceivable in which the substancecarrier (211) covers a number of expandable units (21) and/or surfacesof the sleeve (2) without expandable units (21), for example if thedesign of the substance carrier (211) has a number of separate orconnected partial areas with a substance (212) which may be brought intocontact with the surface of the heart at different areas of the latter.

The shape of the substance carrier (211) or its footprint is representedas being rectangular in this embodiment. Alternatively, the substancecarrier (211) may also be any desired shape in order to be moreefficient when substance is inserted and to be able better to match thegeometry of the area of the heart (900) to be treated. Also conceivableare substance carriers (211) which may contain a number of substances(212), which may be of different kinds, in separate locations.

The substance carrier may also comprise at least one sensor (214). Theat least one sensor (214) may also be an electrode. The at least onesensor (214) may be used to detect at least one parameter in thesubstance carrier or the substance. The at least one sensor (214) may bea concentration measurement sensor, a pH sensor, an oxygenation sensoror a pressure sensor. Other types of sensor are also conceivable. If theat least one sensor (214) is an electrode and if at least two of themare mounted, for example, the electrical potential between the twolocations in which the electrodes have been mounted may be measured. Theat least two electrodes may also be used to apply an electrical voltage.

FIG. 4 shows an embodiment of the supply unit (5). The supply unit (5)may guarantee the supply of energy to the at least one actuator unit(51) of the at least one expandable unit, in particular for actuation ofan inflatable, bellows-like pneumatic chamber. The supply unit (5) maysupply the at least one sensor and/or the at least one electrode withenergy. The supply unit (5) may supply energy to the at least oneelement for setting a parameter, for example at least one heating coil,in the at least one substance carrier, represented in the embodiment asa fillable and emptyable pocket. The energy supply for the at least twoelectrodes for applying an electrical voltage to the substance carrier,the pump device for the at least one reservoir (52) and the at least onecontrol unit may be guaranteed by means of the supply unit (5). Thesupply unit (5) may also comprise at least one fillable and refillablereservoir (52) for at least one substance (212). The at least onereservoir (52) may be exchangeable. The at least one reservoir (52) maybe insertable into the supply unit (5) and removable from the latter.The at least one reservoir (52) may also be designed to be separate fromthe supply unit (5). The at least one reservoir (52) may also bedesigned as a pouch, canister or bottle. The at least one reservoir (52)may be used, via at least one line (521) provided for that purpose, tocarry a substance (212) to the substance carrier or into the substancecarrier. The at least one reservoir (52) may have at least one pumpdevice which may convey the at least one substance (212) to the at leastone substance carrier and pump it out again. With the aid of the atleast one reservoir (52), a continuous circulation of a substance (212)through at least one substance carrier may also be guaranteed in anembodiment as a pocket. In such an embodiment, the circulation may beguaranteed through a pump device. The at least one reservoir (52) mayalso have at least one filter device. The at least one filter device maycomprise at least one membrane. The at least one membrane may besemi-permeable. The at least one membrane may serve to prevent or toexclusively allow at least one substance (212) to pass from one partialspace of the at least one reservoir (52) into the at least one otherpartial space of the reservoir (52). The at least one line (521) may beopen to the at least one substance carrier. The at least one line (521)may also be closed to the at least one substance carrier. The at leastone line (521) may also be permeable to the at least one substancecarrier in respect of at least one substance (212) and at the same timeimpermeable in respect of at least one substance (212). The at least oneline (521) may be semi-permeable in the area in which the at least onesubstance carrier is located. A further discharge line (522) may runaway from the substance carrier back to the reservoir (52). The at leastone discharge line (522) may also be an extension of the at least onedelivery line to the substance carrier. The at least one discharge line(522) may also not be connected to the reservoir (52). The at least onedischarge line (522) may lead into a further, separate reservoir (53).

The supply unit (5) has an energy store with the aid of which the atleast one expandable unit may be driven. The energy store may be in theform of an accumulator (54) which provides electrical energy in order tobe able to expand the expandable unit. The accumulator (54) may bechanged. The supply unit (5) may also contain a pressure reservoir whichprovides a compressed gas in order to be able to expand an inflatablechamber. Suitable gases are, inter alia, compressed air, CO₂ or noblegases. The housing of the supply unit (5) itself may serve as a pressurereservoir housing. This has the advantage that the cavity neverthelessprovided in the housing may be used and an embodiment with a separatepressure reservoir may be dispensed with. The supply unit (5) may alsocontain pumps, valves, sensors and at least one display (57). The supplyunit (5) may also comprise at least one microprocessor (55) on amicroprocessor circuit board (56) which is able to receive and toprocess data from the at least one sensor. If the supply unit (5) iscarried outside the body, the energy to be provided may be transferredthrough a direct connection via a cable, or wirelessly, for examplethrough electromagnetic induction. The at least one microprocessor (55)may also control the actuation of the at least one expandable unitand/or regulate the circulation of the at least one substance (212) fromthe reservoir (52) via at least one substance line into the substancecarrier and if applicable back again into the at least one reservoir(52) or at least one other reservoir (53).

The supply unit (5) may also be designed to be at least partially insidethe body. For example, a separate pressure reservoir, for example forthe purposes of refilling with a pressurized fluid, may lie inside thebody. Alternatively, the at least one accumulator (54) for operation ofthe energy-consuming components of the implant may also lie inside thebody. The data from the at least one sensor may likewise be transferreddirectly via a cable or wirelessly using radio technology, such asBluetooth.

The implant may also comprise a cable harness which connects the atleast one expandable unit and/or the at least one sensor or the at leastone electrode to the supply unit (5). A detailed description of thecable harness is provided in a previous section. In the case of amulti-part cable harness, a cable with a plug part may be mounted on theat least one expandable unit and/or on the at least one sensor or the atleast one electrode and a cable may also be mounted on the supply unit(5) at the end of which a plug part is likewise preferably located.

The supply unit (5) may have a wireless communication interface. Bymeans of the latter, data may be transmitted for the purposes ofassessment or forwarding, for example to the control and monitoringunits described in a previous section. This wireless connection may, forexample, be a WLAN or a Bluetooth connection. All lines, for example atleast one pneumatic line (511), at least one electrical line (551)and/or at least one substance line(521), may, to facilitate handling, becombined in the female part of a multiconnector (58). A detaileddescription of this multiconnector is provided elsewhere.

The supply unit (5) may also have at least one operating element (58)via which at least one function of the supply unit (5) may at least bemonitored. The at least one operating element (58) may also serve to setat least one parameter or one function of the supply unit (5). Forexample, the mass flow of the substance (212) may therefore be monitoredand/or set.

FIG. 5 shows an embodiment of the multiconnector (8) which comprises twocomplementary plug parts, a male plug part (43) and a female plug part(58). The male plug part (43) comprises at least one connection (431) toat least one pneumatic or hydraulic line, at least one connection to atleast one electrical line (432) and at least one connection (433) to atleast one substance line. The complementary female plug part (58)comprises at least one connection (581) to at least one pneumatic orhydraulic line, at least one connection to at least one electrical line(582) and at least one connection (583) to at least one substance line.The embodiment shown in FIG. 5 comprises connections for three pneumaticlines (431, 581), three electrical lines (432, 582) and two substancelines (433, 583). Advantages of the multiconnector (8) are the compactspatial bunching together of different types of line, easy handlingduring coupling and uncoupling and the easy sealability.

The multiconnector (8) may also contain devices for centring (434, 584),for example in the form of a centring pin (434) and complementary shape(584) which guarantees correct orientation for problem-free joining ofthe two complementary plug parts (43,58). The cohesion of the plugconnection may be assured through a coupling mechanism, for example areversible, non-destructive snap lock (435, 585). In the embodimentshown, a snap lock (435) is depicted on the male plug side (43) whichmay be plugged into the complementary lock (585) provided for thatpurpose on the female plug side (58). The snap lock (435) may in someembodiments of the multiconnector (8) also serve as a centring device.

The multiconnector (8) may be sealed against the undesirable entryand/or exit of, for example, fluids, fluid-solid mixtures or granulates.Sealing against other media is also conceivable. Tightness is achievedthrough seals, for example in the form of sealing rings (436) as in theembodiment shown. Each line which has a lumen to be kept tight may beprovided with an individual seal with sealing rings (436). Moreover, themulticonnector (8) may also be sealed overall. In the embodiment shown,this may be a sealing ring (437) mounted on the plug sleeve (438) of themale part (43).

FIGS. 6a and 6b show the process for inserting an embodiment of thepericardium sluice (3) through a surgically made access (905) and asurgically made opening (903) into the pericardial cavity (902). Thepericardium sluice (3) has a proximal end and a distal end. The proximalend may have at least one lamella (32). The distal end has a sealing lip(31). The proximal end of the pericardium sluice (3) faces the operatorduring implantation and the distal end faces the patient. The materialused for the pericardium sluice (3) is explained in more detail in aprevious section. The material of the pericardium sluice (3) may beselected such that the pericardium sluice (3) may undergo considerableelastic deformation. This property is advantageous during the process ofinserting the pericardium sluice (3) into the pericardial cavity (902).The material of at least part of the pericardium sluice (3) may be apolymer. The material of at least part of the pericardium sluice (3) maybe silicone, polytetrafluoroethylene (PTFE) or polyurethane (PU). Thematerial of at least a further part of the pericardium sluice (3) may besteel, a shape memory alloy or a polymer differing from those specifiedabove or a plastic. The sealing lip (31) may, for example, contain acore (311) made out of a stiffer material which may increase thedimensional stability of the pericardium sluice (3). The pericardiumsluice (3) may also be coated on the inside and/or on the outside sothat friction between the pericardium sluice (3) and components insertedtherein may be set. In some areas, greater friction may be advantageous(for example on the outside in contact with body tissue), while in otherareas friction may be reduced by means of the coating, for example foreasier insertion of a delivery system or of the implant.

The pericardium sluice (3) may be made out of at least one part. Thepericardium sluice (3) is preferably designed to be rotationallysymmetrical. It comprises lamellae (32) at the proximal end, a neckregion and a sealing lip (31) which may have a diameter differing fromthe neck region. The sealing lip (31) preferably has a larger diameterthan the neck region of the pericardium sluice (3) so thatself-retention may occur after the pericardium sluice (3) has beeninserted into the pericardial cavity (902). The diameter of the sealinglip (31) may be larger by a factor of 1.0 to 2.0 than the diameter ofthe neck region, while it may be larger by a factor of 1.05 to 1.2 thanthe diameter of the neck region.

The pericardium sluice (3) may, inter alia, serve to produce andmaintain an insertion channel for the minimally invasive implantation ofthe implant. The pericardium sluice (3) may, with its outer surfaceand/or with a sealing lip (31), close and/or seal an opening (903) inthe pericardium (901) and produce an inner lumen as a feed channel forimplantation of the implant.

The lumen of the neck region may have a diameter of 5 mm to 100 mm,preferably 40 mm to 80 mm. The pericardium sluice (3) may be made out ofa hose. Alternatively, the pericardium sluice (3) may consist ofseparate parts for the widening towards the sealing lip (31), the neckregion and the lamellae (32) at the proximal end. The widening area andthe neck region of the pericardium sluice (3) may also be made out ofone part, while the lamellae (32) likewise represent a separate partwhich may be coupled to the other part for example by gluing or weldingor some other joining technique. The materials of the different partsmay be the same or different. It may be advantageous to design one partof the pericardium sluice (3) to be stiffer than the other. The wallthickness of the pericardium sluice (3) may be 0.2 mm to 4 mm. The wallthickness of the pericardium sluice (3) may be 0.4 mm to 2.5 mm. Thesize of the lumen produced by the pericardium sluice (3) may be set viathe diameter. The stiffness of the pericardium sluice (3) may be set bythe wall thickness. The wall thickness may vary locally. In certainplaces, for example in the area of the widening towards the sealing lip(31) or in the neck region, the wall thickness may be greater in orderto facilitate insertion of the implant as the pericardium sluice (3) maybe deformed in a more defined manner. At the proximal end, thepericardium sluice (3) may have lamellae (32) which protrude in thedirection of the longitudinal axis of the sluice. If the pericardiumsluice (3) is thermoformed, for example out of a continuous piece ofhose, or if the pericardium sluice (3) is produced through casting, thelamellae (32) may also be produced by cutting along the axial directionof the pericardium sluice (3) or subsequently coupled to the pericardiumsluice (3), for example by gluing. There may be 1 to 16 lamellae (32),preferably 2 to 6 lamellae (32) along the circumference of thepericardium sluice (3). The lamellae (32) may be arranged equidistantlyalong the circumference, which leads to equally wide lamellae (32). Theymay also be at different distances from one another, which leads tolamellae (32) of different widths. During implantation, the lamellae(32) of the pericardium sluice (3) may be positioned at least partiallyoutside the body and serve to stretch the pericardium sluice (3). Thelamellae (32) may have a spreading effect in that they may be pulled ina radial direction. The lamellae (32) may serve to spread thepericardium sluice (3) radially as evenly as possible. The lamellae (32)may thereby produce the largest possible lumen clinging to the cut inthe skin and body covering. If more axial cuts are made, that is to sayif there are more lamellae (32), the spreading process and the clingingof the pericardium sluice (3) to the shape of the cut in the skin andbody covering are adjusted more finely. Lamellae (32) of differingwidths along the circumference may serve to adjust the spreading and theclinging of the pericardium sluice (3) in different circumferentialsegments of the pericardium sluice (3) with differing fineness in order,for example, to take account of different tissues with differentmaterial properties or the individual body shape of the patient. Thelamellae (32) may serve to adjust the entry depth of the pericardiumsluice (3) by its being pulled more or less strongly. If it is pulledmore strongly, the entry depth of the pericardium sluice (3) may bereduced, while if it is pulled less strongly, the entry depth of thepericardium sluice (3) may be increased. The lamellae (32) may serve toset a constant entry depth of the pericardium sluice (3).

The pericardium sluice (3) may also be made by casting. The pericardiumsluice (3) may also have a differing diameter in the axial direction. Inthe present embodiment, the pericardium sluice (3) may taper from theupper end down to a certain point underneath the upper end and may thenwiden again below that point.

In addition, in the area of the widening of the pericardium sluice (3)towards the sealing lip (31) and/or in the neck region, a porousstructure or a fabric at least partially covering the correspondingareas may be provided, for example a felt, expanded PTFE, Dacron oranother suitable biocompatible synthetic fabric. This has the advantagethat the pericardium sluice (3) grows together better with thesurrounding body tissue in said places and therefore improves both themechanical resilience and the tightness.

An alternative embodiment may comprise a further component, an insertionaid, which may be rotationally symmetrical and preferably consists of astiffer and/or smoother material, that is to say potentially with lowerfriction in relation to components to be inserted, than the pericardiumsluice (3). The measures specified above for setting the friction mayalso be used for this component. This component may serve to temporarilywiden and support the implantation channel and may reduce the tendencyof the pericardium sluice (3) to crumple and kink when it comes intocontact with embodiments of the implant to be inserted. Afterimplantation, this component may remain in or be removed from thepericardium sluice (3).

FIG. 6a shows an embodiment of the pericardium sluice (3) duringinsertion into the pericardial cavity (902). Implantation may be carriedout between two ribs. Owing to its considerable elastic deformability,the pericardium sluice (3) may be passed through an opening (903) in thepericardium (901) which, at its largest elongation, is smaller than thediameter of the pericardium sluice (3) in its undeformed state.

FIG. 6b shows the position of the pericardium sluice (3) after insertioninto the pericardial cavity (902). On account of the size relationshipdescribed above between the opening (903) in the pericardium (901) andthe diameter of the sluice, a non-positive connection may be madebetween the pericardium (901) and the pericardium sluice (3). Thisconnection may increase the stability and the positional accuracy of thepericardium sluice (3) inside the pericardial cavity (902). The neck ofthe pericardium sluice (3) extending towards the sealing lip (31) mayabut against the pericardium (901) and produce a self-retaining effect,thus increasing the stability and the positional accuracy of thepericardium sluice (3) inside the pericardial cavity (902). The sealinglip (31) may likewise increase the stability and positional accuracy ofthe pericardium sluice (3) inside the pericardial cavity (902) becauseit may be an area of increased material stiffness and may therefore beless deformable.

After insertion of the implant, the pericardium sluice may remain atleast partially in the body. The lamellae (32) of the pericardium sluice(3) may also serve another function after implantation of the implant.They may serve to additionally fix the pericardium sluice (3) to thefixing sleeve, for example through wrapping, tying, stitching, stickingor welding. Other methods of fixing are also conceivable. They may alsoperform no function after implantation of the implant. In order tominimize the amount of exogenous material remaining in the body, theselamellae (32) may be separated off. The separation of the lamellae (32)may be carried out by means of a separation device (33), for example apair of scissors or forceps, at a separation plane (34) adequate for theapplication concerned. Separation may also be carried out without anyseparation device if, for example, predetermined breaking points areprovided on the pericardium sluice (3) in the place of intendedseparation at the separation plane (34).

Alternative embodiments may have a multi-part pericardium sluice (3).Such embodiments may, for example, have a sealing element (for examplein the form of a further sealing lip) which may be coupled to a furtherpart so that the two parts achieve the sealing effect together. One partof the seal may be located here inside the pericardial cavity (902), theother outside it. The coupling of the two parts means that thepericardium opening (903) may be closed and is thereby sealed.

FIGS. 7a, b and c show the insertion of the implant (100) via a deliverysystem (9) into the pericardial cavity (902). FIG. 7a shows a positionof the delivery system (9) inside the pericardium sluice (3) just underthe apex of the heart and partially inside the pericardial cavity (902).

The delivery system (9) may be an essentially tubular delivery system(9). The delivery system (9) has a proximal and a distal side. Theproximal side of the delivery system (9) faces the operator duringimplantation and the distal side faces the patient. In this embodiment,the delivery system (9) is represented as a straight, cylindrical tubewith a slanted distal end. The delivery system (9) may also differ fromthe straight, cylindrical tube form. The delivery system (9) may berotationally symmetrical with regard to a straight reference line. Thedelivery system (9) may also differ from rotational symmetry with regardto a straight reference line. The straight reference line may also bethe union of a number of symmetry planes (tube with a polygonal crosssection). The straight reference line may also be the union of focuspoints of all cross sections of the tube (tube with any desired crosssection). The reference axis may also be a reference line. A referenceline may be straight. A reference line may also be curvilinear. Thedefinition of the reference line suggests the possible course of thetube. In its embodiment as a straight, cylindrical tube, the deliverysystem (9) may have a constant wall thickness. The wall thickness of thetubular delivery system (9) may also be variable. The wall thickness maybe variable in the axial direction and in the circumferential direction.The variable wall thickness may serve to influence the insertion of theimplant (100) into the delivery system (9), the passing of the implant(100) through the delivery system (9) or the removal of the implant(100) from the delivery system (9). The variable wall thickness mayfacilitate the insertion of the implant (100) into the delivery system(9), the passing through the delivery system (9) or the removal from thedelivery system (9). A variable wall thickness in the case of anembodiment in the form of a cylindrical tube may mean that the internaldiameter of the tube may change. This may facilitate the insertion ofthe implant (100) into the delivery system (9), the passing through thedelivery system (9) or the removal from the delivery system (9). Avariable wall thickness in the case of an embodiment in the form of acylindrical tube may also mean that the external diameter of the tubemay change. A variable wall thickness in the case of an embodiment inthe form of a cylindrical tube may also mean that the internal andexternal diameter of the tube may change. As a result, the consequencesof both changes in diameter may be combined. In the present embodiment,the wall thickness declines linearly to the end at which the implant(100) is intended to exit. The external diameter of the embodiment shownremains constant here, while the internal diameter increases towards theexit and has a funnel-shaped geometry.

The implant (100) may be inserted into a delivery system (9). Theinsertion of the implant (100) into the delivery system (9) may becarried out through a radial compression of the implant (100). Theassembly consisting of the delivery system (9) and the device accordingto the invention may be carried to the heart (900) through a pericardiumsluice (3) which is located partially inside the pericardial cavity(902) and partially outside the pericardium, but inside the body andpartially outside the body.

In one embodiment in which the frame structure (1) consists of anelastically compressible or self-expanding material, the implant (100)may expand on removal from the delivery system (9) owing to the elasticenergy stored on insertion into the delivery system (9) in the case ofan elastically compressed material or alternatively, in the case of ashape memory alloy, owing to the changed temperature inside the body,and may at least partially surround the heart (900).

FIG. 7b shows the delivery system (9) and an embodiment of the implant(100) which has partially emerged from the delivery system (9) and is inthe process of expansion. At least one sensor (91) and at least oneelement for influencing at least one parameter in or on the deliverysystem (9), for example a heating coil (92), may be mounted on thesurface of the delivery system (9).

The at least one sensor (91) may be mounted on the inner surface or onthe outer surface of the delivery system (9). Alternatively, the atleast one sensor (91) may be incorporated into the wall of the deliverysystem (9). The at least one sensor (91) may serve to detect variousparameters in the delivery system (9) or the surroundings. The sensor(91) may be a temperature sensor, a pressure sensor, a pH sensor, anoxygen sensor, a CO₂ sensor, an optical sensor or a conductivity sensor.The electrical line (94) may connect the sensor to an evaluation device.The at least one sensor may alternatively also be operated wirelessly.

In the present embodiment, the at least one element for influencing atleast one parameter in or on the delivery system (9) is designed as aheating coil (92). By means of the heating coil (92), for example, theexpansion behaviour of the self-expanding frame structure (1) may beset. The at least one element for influencing at least one parameter maybe mounted on the inner surface of the delivery system (9). The at leastone element for influencing at least one parameter may also be mountedon the outside surface of the delivery system (9) or incorporated intothe wall of the delivery system (9). Influenceable parameters maycontrol the temperature inside and/or surrounding the delivery system(9), the concentration of conductivity-influencing substances, the pHvalue of influencing substances or the oxygen and CO₂content-influencing substances inside and/or surrounding the deliverysystem (9). A further parameter may be the static and dynamic frictionbetween implant (100) and delivery system (9) which may be set throughsuitable additions such as lubricant. If the supply, for example, ofelectrical energy is required for operation of the at least one element(94) for influencing at least one parameter in or on the delivery system(9), this may be carried out by means of the electrical line (94).

The end faces of a delivery system (9) may differ from a planar shape atat least one end of the tube. The end faces may take the form of aspatially running level band.

The end faces may also be planar, but tilted towards the central axis ofthe delivery system (9), that is to say the normal of the end face andthe tangent of the reference line of the delivery system (9) at thefocus point of the end faces form an angle that is zero or more. Thedistal end face of the delivery system (9) is preferably slanted,facilitating the insertion of the implant (100). Changing the shape andorientation of at least one end face of the delivery system (9) withrespect to an embodiment with plane end faces, the normals of which areparallel or antiparallel to the tangent of the reference line of thedelivery system (9) at the focus point of the end faces may facilitateand/or improve the insertion of the delivery system (9) into thepericardial cavity (902) through the pericardium sluice (3), theexpansion of the frame structure (1) and the surrounding of a heart(900) through the frame structure (1) and the sleeve (2) becauseanatomical conditions such as the position of the ribs and of the heart(900) may require operational access to the heart (900) at a certainangle to the longitudinal axis of the heart. The slant with respect tothe surface normals of an embodiment with a planer end face may bebetween 30° and 90°, or between 45° and 80°.

The delivery system (9) may be designed to be at least partiallytransparent. The advantage lies in the fact that the embodiment of theimplant (100) inserted into the delivery system (9) may be aligned withthe aid of corresponding markings (24, 93) in relation to the deliverysystem (9) and a precise delivery into the body and insertion into thepericardial cavity (902) may be guaranteed. These markings (24, 93) maybe radiopaque.

FIG. 7c shows an embodiment of the implant (100) which at leastpartially surrounds a heart (900) after removal from the delivery system(9) through the pericardium sluice (3). The pericardium sluice (3) may,as described in a previous section, remain in the body in order to closeoff and seal the opening (903) in the pericardium (901). The deliverysystem (9) may be removed from inside the body again after removal ofthe implant (100) through the pericardium sluice (3).

FIGS. 8a and b show an embodiment of the frame structure (1) which mayprovide form and stability to the implant generally and to a sleeveinserted into the frame structure (1) and which may guarantee theexpansion of the implant after removal from a delivery system into thepericardial cavity.

FIG. 8a shows a three-dimensional view of an embodiment of the framestructure (1) of the implant. The frame structure (1) in this embodimentis represented as a wire framework made out of three wires (14).

The frame structure (1) may be designed in the form of a lattice. Thelattice may consist of a continuous material from which parts have beenremoved or in which the openings have been made. For example, the framestructure (1) may be made out of a tube or an individually formed framestructure sheath in which the openings are cut.

Preferred here is a method in which small slots are made in a tube, forexample by means of laser cutting (“slotted tube”). The slotted tube mayhave a diameter of 4 mm to 30 mm, or a diameter of 6 mm to 20 mm. Theslotted tube may be between 5 cm and 20 cm in length, or between 8 cmand 15 cm in length.

A slotted tube which consists of a shape memory alloy is then stretchedover shaping mandrels and normalized by mean of a heat treatment so thatthe stretched form represents the new natural configuration of the tube.These stretching and heat treatment processes may be repeated withlarger and larger mandrels until the slotted tube may finally bestretched over a form which corresponds to a copy of the heart andwhereby, under heat treatment, the shape of the heart is transferred tothe slotted tube. The production of the mandrel is described in moredetail in a subsequent section. The slotted tube is thereforetransferred into a frame structure (1) consisting of a lattice, theshape of the frame structure (1) corresponding to a copy of the heart.The slots in the tube pass here into the openings of the lattice. Theopenings are delineated here through struts (14). A number of struts(14) of an opening form individual cells of the lattice here. Thelattice may preferably have diamond-shaped cells. The shape of the cellsmay be modified through suitable cutting when slotting the tube.Alternatively, cells with a hexagonal honeycomb structure or cells witha polygonal structure may thereby be produced.

Through suitable cutting, longer or shorter cells may be produced.Through the length and number of the slots, the number of rows of cellsalong the longitudinal axis of the heart of the frame structure (1) isalso defined. Longer slots lead to longer struts (14), while shorterslots lead to shorter struts (14) in the frame structure (1). Longerstruts (14) are more flexible than short struts (14) here. The length ofthe cells is 5 mm to 50 mm, in particular 10 mm to 30 mm. The length ofthe cells may vary from cell row to cell row and may also be the same orvary within a cell row.

As a result of the number of slots along the circumference of the tube,the number of cells along the circumference of the frame structure (1)is determined. Fewer slots along the circumference lead to a greaterwidth of the resulting struts (14), while an increase in the number ofslots along the circumference leads to thinner struts (14). Wider struts(14) are less flexible here than thinner struts (14). In thelongitudinal direction, between 4 and 15 cuts may be made in a row oneafter another, or between 5 and 10 cuts may be made in a row one afteranother. In the circumferential direction, 14 to 80 such rows of cutsmay be distributed around the circumference of the tube, or 20 to 45such rows of cuts may be distributed around the circumference, or 26 to36 such rows of cuts may be distributed around the circumference. Duringproduction, the cuts may be distributed evenly around the circumferenceof the tube (equidistantly), thereby achieving homogeneous structuralstiffness in the lattice. Alternatively, the cuts may be distributedunevenly (not equidistantly) with respect to one another so that areaswith cells having wider struts (greater structural stiffness) and areaswith cells having narrower struts (lesser structural stiffness) may beachieved. Areas in which greater structural stiffness is desired may,for example, be areas which cover the left ventricle of the heart orareas which form the abutment for the expandable units. Areas in which alesser structural stiffness is desired are, for example, areas of theright ventricle.

The wall thickness of the tube into which the slots are cut gives thestrut height of the frame structure (1). A greater strut height leads tostiffer properties of the lattice. A lesser strut height leads to moreflexible properties of the lattice. Through use of a tube withregionally differing wall thickness, areas of lesser or greaterstructural stiffness may therefore be produced. The wall thickness ofthe tube may be between 0.2 mm and 2 mm, preferably between 0.4 mm and1.5 mm, in particular between 0.6 mm and 1 mm. The wall thickness of theframe structure (1) is the same as the wall thickness of the tube.

If the number of slots is the same, a greater tube diameter results in agreater strut width. The method of production guarantees that thelattice of the expanded frame structure (1) may also be compressed againto the size of the tube from which it was cut. This may be helpful inparticular if the frame structure (1) is intended to be inserted into adelivery system described above. However, the frame structure (1) mayalso be compressed to any intermediate size between the fully expanded,heart-shaped lattice and the original tube diameter. By using, forexample, a shape memory alloy, the frame structure (1) may expand intothe heart shape of its own accord upon implantation/removal from thedelivery system. The exerting of external forces through further devicesis unnecessary when using a shape memory alloy. In particular, thelength of the cells and/or struts (14) of the lattice determines theopening angle on expansion of the frame structure (1) here, inparticular in the case of the self-expandable frame structure (1).

Instead of a lattice, the frame structure (1) may also consist of a meshof wires (14).

The wires (14) form crossing points which may be firmly connected to oneanother. For example, the wires (14) may be welded to one another at thecrossing points. The connecting of the wires (14) at crossing pointsincreases the stability of the frame structure (1). The crossing pointsmay also not be connected to one another. This may increase theflexibility of the frame structure (1) and hence make the framestructure (1) easier to compress. This may be helpful in particular ifthe frame structure (1) is intended to be inserted into a deliverysystem with a catheter having a smaller diameter. The frame structure(1) may also have certain crossing points firmly connected to oneanother and other crossing points not firmly connected to one another.Through a suitable choice of crossing points which are firmly connectedto one another and crossing points which are not firmly connected to oneanother, the stability and flexibility of the frame structure (1) may beadjusted. Areas which require greater stability in the implanted statemay be stabilized through the connection of wires (14) at crossingpoints. These may, for example, be areas which serve as abutments forexpandable units. Such abutments may be located directly under anexpandable unit or next to areas with expandable units. Areas whichrequire greater flexibility may be areas which have to be compressed toa greater extent than other areas on insertion into a delivery system.Areas which may require greater flexibility may also be areas in whichgreater flexibility helps the natural movement of the heart.

Adjustments may also be made through the choice of material used,through changes of material in certain areas or through application of,for example, energetic radiation, such as heat. The frame structure (1)preferably has openings which are formed by the wires (14) of a wiremesh, the struts (14) of a lattice or the holes in a frame structuresheath. These openings allow the compression of the frame structure (1),they allow the exchanging of substances from inside the frame structure(1) with areas outside the frame structure (1) and vice versa, theyreduce the quantity of material to be used for the frame structure (1)and they allow greater flexibility of the frame structure (1). Formswhich can only be produced with difficulty using continuous materialscan be formed more easily with mesh-like or lattice-like structures. Theopenings may be quadrangular, diamond-shaped, round or oval. Theopenings defined by the wires (14), the struts (14) or the holes in aframe structure sheath have a diameter of approximately 1 mm to 50 mm,preferably from 3 mm to 30 mm, preferably from 5 mm to 20 mm. Thediameter of an opening is defined as a pin opening, that is to say thediameter of the opening constitutes the largest diameter of acylindrical pin which may be passed through an opening (a cell, a hole).

The frame structure (1) preferably consists of a material which allowsexpansion. The frame structure (1) is preferably formed from a materialwhich is selected from the group consisting of nitinol, titanium andtitanium alloys, tantalum and tantalum alloys, stainless steel,polyamide, polymer fibre materials, carbon fibre materials, aramidefibre materials, glass fibre materials and combinations thereof. For aself-expanding frame structure (1), a material which is made at leastpartially out of a shape memory alloy is suitable. Materials for shapememory alloys are, for example, NiTi (nickel-titanium; nitinol), NiTiCu(nickel-titanium-copper), CuZn (copper-zinc), CuZnAl(copper-zinc-aluminium), CuAlNi (copper-aluminium-nickel), FeNiAl(iron-nickel-aluminium) and FeMnSi (iron-manganese-silicon).

The frame structure (1) may also consist of a plastic, a compositematerial or a polymer, which have sufficient stiffness for expansionunder the conditions described. For example, the frame structure (1) maybe made out of polyethylene and is preferably produced by a castingprocess, for example injection moulding. Other plastics, fibre materialsor composite materials are also conceivable.

The frame structure (1) preferably has a shape adapted to the individualshape of the patient's heart. The individual shape of the patient'sheart may be reconstructed here from CT or MRT image data. The framestructure (1) is open at the distal, upper end (15) from the operator'spoint of view. The upper, distal edge of the frame structure (1)preferably has loops of a wire or stirrup which are formed from struts(14). The loops or stirrups may serve as anchoring points for a sleevewith at least one expandable unit. At the proximal, lower end of theframe structure (1) from the operator's point of view there ispreferably an opening (16) through which one or more electric lines ofthe at least one sensor or the at least one electrode and/or lines ofthe at least one expandable unit may be passed. The shape of the framestructure (1) at least partially represents the shape of a naturalheart, preferably the lower part of a heart. Specifics regarding theshape of the frame structure (1) are explained in more detail in asubsequent section of the description.

If there are two or more struts (14), the at least two struts (14) maybe the same length, but may also be of different lengths. The crosssection of the at least one strut (14) may be rectangular. The crosssection of the strut (14) may also differ from the rectangular form, andmay for example also be round, elliptical or polygonal. The at least onepart of the frame structure (1) may consist of several wires (14) whichmay in each case be coupled in pairs. At least one couplable pair mayalso be designed to be uncoupled. Alternatively, the at least one partof the frame structure (1) may consist of at least one strut (14). Theat least one part of the frame structure (1) may also consist of severalstruts (14) which may in each case be coupled in pairs. At least onecouplable pair may also be designed to be uncoupled. The at least onewire (14) or the at least one strut (14) may be coupled so thatdifferent segments are connected to one another along the at least onewire or the at least one strut (14).

In the present exemplary embodiment, the three shaped wires (14) areconnected to the respective neighbouring wire through two couplings (13)in each case. A coupling (13) may be carried out through materialbonding, through positive locking and/or through non-positive locking Ifthe coupling (13) is designed as a material bond, the coupling partnersmay, for example, be welded or stuck to one another. If the coupling(13) is designed as a positive connection, this may, for example, becarried out through complementary coupling elements (13) on the at leasttwo wire or strut segments to be connected. The coupling elements (13)here may be part of the at least two wire or strut segments, for examplein the form of hooks, eyelets, buttons, loops or the complementarycombination thereof for the respective wire segment or strut segmentpair to be coupled. Alternatively, the connection partners, if designedas wires (14), may also be weaved or twisted. The coupling elements (13)may also be at least one individual component, for example in the formof rings, sleeves, clips, wires or clamps. The positive coupling (13)may also be carried out through at least one Velcro fastening and/orzip. If the coupling (13) is carried out through non-positive locking,the ends of the at least two wire or strut segments may be tied togetherusing threads, fibres or cables. The ends of the at least one wire or ofthe at least one strut (14) may be brought together at the lower end ofthe implant. The ends may be coupled to one another. However, the endsmay also be left uncoupled. The two ends of the at least one wire may becoupled. If there are at least three wires (14), one end of one may alsobe connected to one end of the neighbouring wire (14). The ends of theat least one wire (14) or the at least one strut (14) may serve toaxially stiffen the implant (parallel to the longitudinal axis of theheart) and to axially position it securely in place. The axialpositioning securely in place is achieved by the ends of the at leastone wire or of the at least one strut (14) being affixed on or in thefixing sleeve which runs from the present embodiment of the implant awaytowards the supply unit. This connection may be brought about throughpositive locking, non-positive locking or material bonding. In the caseof positive locking, the connection may be designed as the coupling (13)of two complementary connection partners in the form of a connectionwith feather keys, in the form of a hook-eyelet connection, abutton-loop connection or a hook-loop connection. In the case ofnon-positive locking, this connection may be carried out in the form ofa clamp connection or a connection using a threaded pin. In the case ofmaterial bonding, this connection may be carried out in the form of anadhesive connection or a welded connection.

The stiffness of the frame structure (1) in the axial, radial andcircumferential direction may be set through the number of wires orstruts (14). The stiffness of the frame structure (1) increases with theincreasing number of wires (14) or struts (14) used. Alternatively, thestiffness of the frame structure (1) may be set through the number ofpair-wise couplings of at least two wires (14) or struts (14). Thestiffness of the frame structure (1) increases with the increasingnumber of couplings (13). The stiffness of the frame structure (1) mayalso be adjusted via the cross section of the at least one wire or thecross section of the at least one strut (14). A larger cross-sectionalsurface area may lead to greater stiffness of the frame structure (1).The thickness of the at least one wire or of the at least one strut (14)may be between 0.2 mm and 2 mm. The thickness of the at least one wireor of the at least one strut (14) may be between 0.4 mm and 1 mm. In thecircumferential direction, the stiffness of the frame structure (1) maybe set by an alternating course of the at least one wire or the at leastone strut (14). The alternating course may be periodical. However, itmay also differ from a periodical form. The parameters playing a role insetting the stiffness are the amplitude of the alternating course in thetransverse direction and the number of maxima and minima of the wire orstrut course. In the case of a periodic wire or strut course, the numberof periods of the wire or strut course is reflected in the periodlength, a period having one maximum and one minimum. In the case of aperiodic wire or strut course, an embodiment may be realized insinusoidal form, in triangular form, in rectangular form, in polygonalform, sectionally in semicircular form or in a combination of theseforms. The combination of the forms specified above may also lead to anaperiodic wire or strut course when viewed over the entirecircumference. The wire or strut course may be the same in each part inan embodiment of the frame structure (1) consisting of at least twoparts or may differ between the parts. The amplitude of the wire orstrut course influences the stiffness of the frame structure (1)primarily, but not exclusively, in the circumferential and in the radialdirection. An effect influencing axial stiffness may also be achieved.The expansion and compression behaviour of the expandable framestructure (1) may be influenced through the amplitude of the wire orstrut course. The amplitude of the wire or strut course may be between 0mm and half the total height of the frame structure (1) (the distancebetween the upper and lower ends of the frame structure (1)). Theamplitude may be between 4 mm and 10 mm. The number of periods of thewire or strut course along the circumference may likewise be used toinfluence the stiffness of the frame structure (1) primarily, but notexclusively, in a radial and circumferential direction. An effectinfluencing axial stiffness may also be achieved. The number of periodsin the wire or strut course along the circumference may be between 0 and72, or may also be between 12 and 36. All of the possible ways ofinfluencing axial, radial and circumferential stiffness specified in thedescription of the frame structure (1) may also be used in combination.

In the case of embodiments of the frame structure (1) consisting of atleast one wire, at least one strut (14) may also be used and may becoupled to the at least one wire (14), which may additionally increasethe stability and stiffness of the frame structure (1). In alternativeembodiments of the frame structure (1) consisting of at least one strut(14), at least one wire (14) may also be used and may be coupled to theat least one strut (14), which may additionally increase the stabilityand stiffness of the frame structure (1). The axial, radial andcircumferential stiffness of the frame structure (1) may also be setthrough the targeted combination of wires (14) and struts (14).

The material of the at least one wire or of the at least one strut (14)may enable the frame structure (1) to pass from a non-expanded state toan expanded state. The material of the at least one wire or of the atleast one strut (14) may be a shape memory alloy. The material of the atleast one wire or of the at least one strut (14) of the frame structure(1) may also differ from a shape memory alloy. The material may also bea spring steel or a polymer. The polymer may be polyurethane (PU),polypropylene (PP), polyethylene (PE), polycarbonate (PC), polyamide(PA), a superelastic polymer or a shape memory polymer. The framestructure (1) may also consist of a biodegradable material, for examplepolylactide, cellulose or polyglycolide, because this may have theadvantage that an embodiment of the implant without any cable harness orsupply unit, which consists overall of at least one biodegradablematerial, no longer has to be removed from the body after it has carriedout its function. In the case of embodiments of the implant in whichonly the frame structure (1) consists of at least one biodegradablematerial, this may be advantageous because, for example, the risk ofinjury to the surrounding tissue caused by the frame structure (1) isreduced and the process of explantation without a frame structure (1)may be considerably easier. Such a frame structure (1) is broken down bythe body over time. A frame structure (1) made out of a polymer mayconsist of struts (14) which can be deformed elastically from theexpanded state in order to compress the frame structure (1) and insertit into a delivery system. On removal into the pericardial cavity, theframe structure (1) returns to its expanded state again. The expansionand compression of the embodiment of a frame structure (1) consisting ofa polymer may be carried out with the aid of a shape memory effect orwithout the use of any shape memory effect. With increasing stiffness,the suitability of the frame structure (1) as an abutment, for examplefor the at least one expandable unit, may increase. In the case of lowstiffness, a small amount of material may be used for the framestructure (1). The stiffness may be sufficient to provide the sleevewith position and shape. With a low but sufficient stiffness of theframe structure (1), the weight of the implant may be reduced. With alow but sufficient stiffness of the frame structure (1), insertion intoa delivery system may be facilitated. The frame structure (1) may alsoprimarily serve to position and shape a sleeve and may serve less as anabutment.

The frame structure (1) may have at least one recess which ensures thatanatomical structures are not spatially impaired, for example theinferior vena cava. The recess may be produced such that thecircumferential wire or strut course provides a recess in the area ofthe anatomical structure which is not supposed to be compressed.

At least one wire (14) or at least one strut (14) may also run in thecircumferential direction. The at least one wire (14) or the at leastone strut (14) in the circumferential direction may increase thestability of the frame structure (1). The at least one wire (14) or theat least one strut in circumferential direction may increase thestiffness in the circumferential direction. The number of wires (14) orstruts in the circumferential direction may be between 0 and 10. It maybe between 0 and 3. At least one wire (14) or at least one strut mayalso be partially axially orientated and partially orientated in thecircumferential direction. The at least one wire (14) or the at leastone strut (14) in the circumferential direction may increase thestability of the frame structure (1). The at least one wire (14) or theat least one strut (14) in the circumferential direction may increasethe stiffness both in the axial direction and in the circumferentialdirection.

FIG. 8b shows a two-dimensional unrolling of the frame structure (1). Inthe present embodiment, the unrolled frame structure (1) consists ofthree wires (14), the two ends of each of them being brought together atthe lower end of the frame structure (1). There they may be connectedwith the aid of a coupling (13). Possible connections may be an adhesiveconnection, a welding connection, a non-positive connection such astying up, or a positive connection with hooks, eyelets, buttons orloops. At least one end of the at least one wire (14) or of the at leastone strut (14) of the frame structure (1) may be clipped off afterwardsor beforehand. The clipping of the frame structure through a separationdevice (17) or through predetermined breaking points provided insuitable places may reduce the quantity of exogenous material introducedinto the body. The clipping may be perceived as a further option foradjusting axial or rotatory stiffness.

The at least one wire (14) may form a recess which may serve the purposeof not spatially impairing anatomical structures such as the inferiorvena cava.

Using a suitable method of production, for example by laser cutting,segments of the frame structure (1) may alternatively be cut out of asheet or a half-tube. The frame structure (1) may be produced throughsubsequent shaping (for example bending or contorting of the framesegment which is flat after the first production step) and coupling ofthe segments together.

FIGS. 9a and b show a slotted tube (20) with the pattern (201) indicatedand the process of pulling a slotted tube (20) onto a mandrel (30) whichmay be derived from a three-dimensional copy of a heart. The process isintended to produce a patient-specific geometry of the frame structurewhich may be made out of an initially continuous, tubular semi-finishedproduct.

FIG. 9a shows by way of indication a number of rows of cuts (202)orientated in the longitudinal direction of the tube, it being possiblefor neighbouring rows to be offset with respect to one another. Theoffsetting may influence the shape of the cells which are produced whenthe slotted tube is widened. Moreover, a corresponding pattern (201) mayalready provide the recess (203) which, after widening of the tube,leads to a notch being created along the circumference which preventsthe spatial impairment of the vena cava or other relatively largeanatomical structures. A suitable pattern (201) may also alreadydetermine the shape and length of the extension struts.

FIG. 9b shows a partially removed slotted tube (20) and an embodiment ofthe shaping mandrel (30). The mandrel (30) comprises a circumferentialrib (301) in the proximity of its base and a circumferential rim madeout of bores for the insertion of fixing bolts (302). Thecircumferential rib (301) may correspond to the extensive shape of theimplant sought. One embodiment may, for example, take account of therecess (304) for the vena cava or other relatively large anatomicalstructures with the aid of the course of the circumferential rib (301).The rib (301) may be used here to set the circumferential shape of theimplant precisely. In the state in which the tube (20) has been pulledover the mandrel (30) until it stops at the rib (301), the tube (20) maybe affixed, with the aid of fixing bolts (302), which are inserted intothe bores (303) provided for that purpose through the openings producedas a result of the slotting of the tube, until the widened form hasbecome established in the precursor of the frame structure. If theslotted tube (20), for example, consists of a shape memory alloy, theestablishment of the widened geometry may be carried out throughnormalization. Metallic frame structures which do not consist of shapememory alloys are also conceivable.

FIGS. 10a and b show an embodiment of a pocket (50) which mayaccommodate a substance carrier. The pocket (50) may be filled with asubstance via an opening (501) in the lateral surface facing the upperedge of the sleeve (2). The pocket (50) may have a removable area (502)on the surface facing the heart. Removal thereof results in thetemporally and spatially well-defined release of the substance.

FIG. 10a shows the unassembled pocket (50) which may accommodate asubstance carrier and a three-dimensional depiction of the pocket (50).The pocket (50) may be affixed in the sleeve (2). Embodiments of asubstance carrier are described in more detail in a subsequent section.If the device in an embodiment also has an expandable unit (21) whichmay be incorporated into the sleeve (2), the at least one pocket (50)may be affixed to the end face of an expandable unit (21). However, thepocket (50) may also be affixed somewhere in the sleeve (2) where thereis no expandable unit (21). The present embodiment is designed such thatthe end face of the expandable unit (21) or the sleeve (2) forms theback of the at least one pocket (50). Alternatively, the pocket (50) mayalso have an enclosed space before coupling to the sleeve (2) and/or atleast one expandable unit (21). In this case, a separate couplingmechanism may be required. The coupling mechanism may be designed suchthat coupling may also be carried out only under operating conditionsand by a person in the operating theatre.

The width, length and depth of a pocket (50) or of a substance carrierare in each case defined as the dimensions of the pocket (50) or of thesubstance carrier in the circumferential direction of the heart, thelongitudinal axis of the heart and in a radial direction perpendicularlyto the longitudinal axis of the heart. The at least one pocket (50) maybe between 10 mm and 80 mm wide, preferably between 20 mm and 50 mm. Thelength of a pocket (50) may be between 10 mm and 80 mm, preferablybetween 20 mm and 50 mm. The pocket (50) may be between 0.05 mm and 8 mmdeep. The at least one pocket (50) may be between 1 mm and 3 mm deep.The material of the at least one pocket (50) may be identical to thematerial of the sleeve (2) or the material of the at least oneexpandable unit (21). The material of the at least one pocket (50) mayalso differ from the material of the sleeve (2) or the material of theat least one expandable unit (21). The material of the at least onepocket (50) may be a polymer. The material of the at least one pocket(50) may be polyurethane, silicone or polytetrafluoroethylene (PTFE).The pocket (50) may be made out of the same material as the sleeve (2)and/or an expandable unit (21). The pocket (50) may be incorporateddirectly into a sleeve (2) and/or an expandable unit (21), whereby thepocket (50) is part of the sleeve (2) or of an expandable unit (21).

The pocket (50) may, for example, first be cut as a two-dimensionalunassembled part from a sheet made out of at least one of the materialsspecified above and then joined together to produce itsthree-dimensional form.

The at least one pocket (50) may have an opening (501) on one surfacewhich may be used to insert a substance into the pocket (50) in thepresent embodiment. The at least one pocket (50) may have a removablearea (502) on the surface facing the heart. The removable area (502) maybe rectangular. The removable area (502) may be of round, elliptical orpolygonal shape or a combination thereof. The removable area (502) may,in its implanted state, be removable from the pocket (50) from outsidethe body by means of a mechanism which uses traction elements (404). Themechanism and its fraction elements (404) may at least partiallyconsist, for example, of threads, cords, rods, strips (for example ofplastic) or similar loadable components. If this area (502) is pulledaway, an opening is made in the at least one pocket (50) through whichthe substance held inside the at least one pocket (50) can come out,that is to say into the sleeve (2), and enter into contact with theheart at the location intended for release of the substance. Theremovable area (502) of the at least one pocket (50) may be pulled awaythrough threads mounted in this area (502). The removable area (502) mayhave at least one perforation (403) of the material of the pocket (50)at its edges in order to be able to allow the process of pulling away.The removable area (502) may also have at least one dummyjoint/predetermined tear point (403) at its edges which may allow theprocess of pulling away. The removable area (502) may serve to ensurethe temporally delayed release of a substance inside the pericardialcavity. The pocket (50) per se may serve to protect the substance, forexample against friction or during compression over the course of theimplantation process. After implantation, this protection is no longerrequired and may therefore be removed.

Alternatively to the removable area (502) on the side of a pocket (50)facing the heart, an area (502) may be provided which is at leastpartially made out of a biodegradable and/or permeable material. Thishas the advantage that a substance is mechanically protected during theimplantation process and may subsequently be released. Unlike with theremovable area (502), no part therefore has to be removed from the bodyany longer, which facilitates the implantation process. The release ofthe substance may also be carried out in a time-controlled manner byusing materials with a different dissolution and/or decomposition rate,with a defined wall thickness or with a specific permeability. Examplesof such decomposable or soluble materials are natural polymers such ascollagen or alginate, polysaccharides such as hyaluronic acid andgelatine and/or synthetic aliphatic poly(hydroxycarboxylic acid)polyesters such as poly(ε-caprolactone), polylactide, polyglycolic acid,poly(4-hydroxybutyric acid), poly(3-hydroxybutyric acid),poly(2-hydroxybutyric acid) or their copolymers and/or self-assemblingpeptides such as peptides based on arginine-glycine-aspartate aminoacids. Examples of permeable substances are methylcellulose,polyurethanes or their copolymers, the porosity depending on the methodof production. The at least one pocket (50) may also consist entirely ofa biodegradable and/or a permeable polymer.

The pocket (50) may also comprise a radiopaque marking (505), with theaid of which [lacuna] for example in the case of a [lacuna] separatelyto the sleeve (2) and/or the at least mountable pocket (50) [lacuna]

FIG. 10b shows an embodiment of the implant (100) which is partially cutaway to provide a view of the inside of the sleeve (2). A pocket (50),which may accommodate a substance carrier, is affixed to the presentexpandable unit (21). The removable area (502) on the end face of thepocket (50) in the form of a rectangle is connected to the two uppercorners with threads which are guided through the opening (26) of thesleeve (2) lying underneath through the encased cable harness (4) to theoutside, that is to say out of the body.

FIG. 11 shows various embodiments of the substance carrier (40).

FIG. 11a shows the production and insertion of a substance carrier (40)into a pocket (50) which may be provided for the purpose ofaccommodating a substance carrier (40) during the insertion of thesubstance carrier (40) into the pocket (50) and in the installed state.A substance (403) which may have a therapeutic effect may be applied tothe substance carrier (40). The at least one substance (403) may beapplied to the substance carrier (40), for example by application,spreading, gluing, vapour deposition, populating with cells, casting orthermobonding.

In FIG. 11 a, the substance carrier (40) is represented as beingmulti-part, consisting of a frame (401) and a membrane (402) which isstretched through the frame (401) and on which at least one substance(403) may be applied. The membrane (402) may be connected to the frame(401), for example by sticking The frame (401) may also be incorporatedinto the membrane (402), for example moulded. The frame (401) may serveto facilitate the process of inserting the substance carrier (40) intothe at least one pocket (50). The pocket may have a removable area (502)which may have a perforation (503). The frame (401) and the substancecarrier (40) may be compressed for the purposes of insertion into apocket (50). In the non-compressed state, the frame (401) may guaranteethe correct positioning of the substance carrier (40) and the substance(403) applied thereto. The frame (401) may be dimensioned such that itmay be inserted in its compressed state into the pocket (50) through anopening in the pocket (50) and is wider than the opening in thenon-compressed state. As a result, before implantation of the implant,simple insertion of the substance carrier (40) may be guaranteed and anydislocation of the substance carrier (40) after implantation of theimplant may be prevented. The frame (401) of the substance carrier (40)may be made out of polyurethane (PU), silicone, polytetrafluoroethylene(PTFE), metal or a metal alloy, in particular a shape memory alloy, or acombination thereof. The at least one material may be a shape memoryalloy. The membrane (402) may be made out of polyurethane, silicone orpolytetrafluoroethylene (PTFE). The membrane (402) may also consist ofthe same material as the frame (401). If the membrane (402) and frame(401) consist of the same material, the substance carrier (40) may alsobe formed as one part. The frame (401) may then consist of an amassingof the material, for example from a thickening of the material at theedge of the substance carrier (40). Alternatively, a single-partsubstance carrier (40) may be characterized in that material has beenremoved from the membrane area or subsequently weakened, for examplethrough application of radiation or chemicals.

The membrane (402) may be made out of a different material than theframe (401). The membrane (402) may have an incorporated frame (401).The frame (401) may be made out of a self-expanding material. The frame(401) may be made out of a shape memory alloy and/or out of asuperelastic material so that the substance carrier (40) may betransferred from a non-compressed form into a compressed form for thepurposes of insertion into a pocket (50). The frame (401) may be madeout of nitinol. The substance carrier (40) may be considerablydeformable. The substance carrier (40) may be deformable for thepurposes of insertion into a pocket (50) such that its width in acompressed state is smaller than or the same as the size of an openingin a pocket (50). The at least one substance carrier (40) may be between10 mm and 80 mm wide, preferably between 20 mm and 50 mm. The at leastone substance carrier (40) may be between 10 mm and 80 mm long,preferably between 20 mm and 50 mm. The at least one substance carrier(40) may be between 0.5 mm and 5 mm thick, preferably between 1 mm and 3mm. The frame (401) and/or the substance carrier (40) may also differfrom the flat shape and be three-dimensionally adapted to the curvatureof a cylinder, a ball or a copy of a heart.

In the present embodiment, the substance carrier (40) may be insertedinto the pocket (50) through an opening in the pocket (50). In thepresent figure, a substance carrier (40) is represented with arectangular frame (401). The opening in the pocket (50) may be smallerthan the lengths of the edges of the substance carrier (40) and/or ofthe frame (401). At least one edge of the frame (401) may be wavy,meandering, contorted or bent in form. The difference in the form of atleast one edge of the frame (401) from the straight form may make theframe (401) easier to compress. In one embodiment in which at least partof the substance carrier (40) consists of an elastic and/or superelasticmaterial, the substance carrier (40) may, after deformation on insertioninto the pocket (50) through the opening in the pocket (50), return toits initial geometry before deformation again. As a result, a betterseating of the substance carrier (40) in the pocket (50) may beachieved. The frame (401) of the substance carrier (40) may consist ofat least one wire. The frame (401) of the substance carrier (40) may beproduced by separating a profile from a previously continuoussemi-finished product, for example by stamping from a sheet or lasercutting from a tube, a sheet or a film. Alternatively, the frame (401)may also be produced by a generative method of production, such ascasting, sintering or a rapid prototyping method. The frame (401) mayconsist of a coherent profile. If the frame (401) consists of at leastone wire, the ends of the at least one wire may be connected, forexample by gluing, welding, riveting, hooks and/or eyelets or a sleeve,thereby producing an enclosed frame (401). The profile or a wire of theframe (401) may also not be connected in at least one place and an openand/or interrupted frame (401) is produced. An enclosed frame (401) hasa greater structural stiffness and may also ensure a certain formalstability of the substance carrier (40) when forces are exerted throughmovement of the heart or when load is applied by an expandable unit, thesleeve (2) or another part of the implant. An open frame (401) has theadvantage that the substance carrier (40) is easier to compress than acomparable substance carrier (40) with an enclosed frame (401). The wirewinding or the profile may have a form at least partially differing froma straight line. The at least one wire or the profile of the frame (401)may have a periodically alternating directrix. The directrix may also beaperiodically alternating. If the material of the frame (401) is a shapememory alloy, the frame (401) may be transformed into a defined shapewith the aid of at least one heat treatment.

FIG. 11b shows a further embodiment of the substance carrier (40) duringinsertion of the substance carrier (40) into the pocket (50) and in theimplanted state. The pocket (50) shown corresponds here to that in FIG.11 a. The present embodiment of the substance carrier (40) is ellipticaland comprises a membrane (402) which contains at least one wireincorporated into the membrane (402) for stretching the membrane (402).In the present embodiment, at least one of the two main axes may belonger than the edge, which is parallel to this main axis, of the pocket(50) which is rectangular in this embodiment, which means that theelliptical substance carrier (40) is better fixed in the rectangularpocket (50) through the resulting clamping effect. The pocket (50) mayalso differ from the rectangular shape. In this case, it may beadvantageous also to change the shape of the substance carrier (40) andadapt it to the shape of the pocket. Advantages of the ellipticalembodiment are, amongst other things, the simple geometry and the easyproducibility of the substance carrier (40).

FIG. 11c shows a further embodiment of the substance carrier (40) and ofthe pocket (50) during insertion of the substance carrier (40) into thepocket (50) and in the implanted state. Materials which may be used forthe substance carrier (40) and the pocket (50) are specified in aprevious section. The embodiment of the substance carrier (40) shown isin two parts. It comprises a frame (401) and a membrane (402) to whichthe at least one substance (403) may be applied. The previousdescriptions correspondingly apply to the substance carrier (40), theframe (401) and the membrane (402). FIG. 11c also shows a possible wayof connecting the substance carrier (40) to the frame structure (1), thesleeve (2), the end face of the at least one expandable unit (21) and/orthe pocket (50). For that purpose, the substance carrier (40) may haveat least one coupling element (404). The at least one coupling element(404) may be part of the frame (401), for example a longitudinal strutor a wire element, and protrude from the frame (401). The couplingelement (404) may be designed at the end such that coupling to anothercomponent of the device is made possible. The coupling element (404) mayextend as far as a structurally bearing component of the frame structure(1) or as far as another coupling element (404) of the sleeve (2), ofthe pocket (50) and/or of an expandable unit (21). FIG. 11c shows fourcoupling elements, two of the coupling elements protruding laterallyaway from the frame (401) of the substance carrier (40) and connectingthe latter by means of hooks to two wires or struts of the framestructure (1). The other two coupling elements in FIG. 11c protrudeupwards away from the frame (401) and connect the latter to the implantthrough an opening in the sleeve (2) and on the “upper rim” of the framestructure (1). The coupling may be carried out by means of positivelocking, non-positive locking and/or material bonding. In the case ofpositive coupling, the at least one coupling option may include a loop,a hook, an eyelet, a button or at least one Velcro fastening and/or zip.In the case of non-positive coupling, an adhesive connection or aconnection by tying with threads, lamellae or cables may be used. In thecase of materially bonded coupling, the connection may be a weldedconnection or an adhesive connection. In the present embodiment, thecoupling is represented with four coupling elements. A substance carrier(40) may also have one, two, three, four, five, six or more couplingelements.

The pocket (50) in the present embodiment may have two openings atopposite ends. The substance carrier (40) may be inserted into thepocket (50) through the first opening and exit again through the secondopening. The pocket (50) may have a removable area (502) on the end facewhich may be delimited by a perforation (503) and/or a dummy joint.After insertion and fixing of the substance carrier (40) to the sleeve(2) and/or to the end face of the at least one expandable unit (21)and/or the frame structure (1), the removable area (502) may be removed.Alternatively, the removable area (502) is made, as described above, atleast partially out of a biodegradable and/or permeable material. Theremovable area (502) may be formed according to the description in FIG.10. Following the removal of the removable area (502), the substance(403) which is located on the substance carrier (40) may be broughtdirectly into contact with the surface of the heart. The pocket (50) mayhave the function of protecting the substance carrier (40) in thenon-expanded state of the implant. The pocket (50) may increase thepositional accuracy of the substance carrier (40). An advantage of theembodiment shown in FIG. 11c is the additional fixing of the substancecarrier (40) in the frame structure (1) with simultaneous protection ofthe substance carrier (40) through the pocket (50) which is shown herein the form of a protective sleeve.

FIG. 11d shows a further embodiment of a substance carrier (40)consisting of a membrane (402) which may be directly connected to theinside of the sleeve (2) and/or to the end face of the at least oneexpandable unit (21). In this embodiment, a pocket (50) and/or a frame(401) may be dispensed with. The connection between the substancecarrier (40) and the surface of the sleeve (2) and/or the end face ofthe at least one expandable unit (21) may be carried out in the waysmentioned in a previous section of the description. In particular, theat least one coupling (27, 404) may be designed as a plug connection oras an adhesive connection. The at least one coupling (27, 404) may alsobe carried out through at least one button-eyelet connection or at leastone Velcro fastening connection. In the present embodiment, thesubstance carrier (40) may have four selective coupling options. Thecoupling option (27, 404) may also be designed as a planar coupling. Thecoupling (27, 404) to the surface of the sleeve (2) and/or to the endface of the at least one expandable unit (21) may require at least onecoupling pair (27, 404), it being possible for one coupling partner tobe affixed to the substance carrier (40) and the other coupling partnerto be fixed to the surface of the sleeve (2) or the end face of the atleast one expandable unit (21). The application of the substance (403)to the substance carrier (40) may correspond to a previous description.Advantages of such an embodiment are the simplified mounting of thesubstance carrier (40) in the sleeve (2) or on an expandable unit (21)and the fact that a pocket (50) is not additionally required in order tokeep the substance carrier (40) in position.

FIG. 11e shows a further embodiment of the substance carrier (40). It issimilar to the embodiment which is described in FIG. 11 d. The substancecarrier (40) may consist of only one membrane (402) to which a substance(403) may be applied and may contain no frame (401). The coupling (27,404) between the underside of the substance carrier (40) and the insideof the sleeve (2) and/or the end side of an expandable unit (21) isdesigned to be planar in this embodiment. The at least one planarcoupling option (404) may at least partially cover the underside of thesubstance carrier (40). The underside of the substance carrier (40) mayalso have two, three, four, five, six or more planar coupling elements(404) which in each case at least partially cover the underside. Theunderside of the substance carrier (40) may have one, two, three, four,five, six, seven or more planar coupling elements (404).

The coupling partner of the at least one planar coupling element (404)may be the surface of the sleeve (2) and/or the end face of the at leastone expandable unit (21). The surface of the sleeve (2) and/or the endface of the at least one expandable unit (21) may also have at least onecoupling element (404) which serves as a coupling partner for the atleast one coupling element (404) on the underside of the substancecarrier (40). The at least one planar coupling element (404) on theunderside of the substance carrier (40) may have at least one planarcover (405) which may be removed in order to release the at least oneplanar coupling element (404) on the underside of the substance carrier(40). The complementary coupling area (27) is located on the sleeve (2)and/or the at least one expandable unit (21).

Alternatively, the planar cover (405) may also remain on the substancecarrier (40) if it itself allows an adhesive connection and also has atleast one additional function. For example, this additional layer (405)may be at least partially electrically conductive, raising thepossibility of applying a potential to the substance carrier (40) or thesubstance (403). This may influence the growth of, for example, stemcell cultures. In the present embodiment, the cover (405) of the atleast one planar coupling element may be removed. The substance carrier(40) in the present embodiment may be mounted and affixed directly ontothe surface of the sleeve (2) and/or the end face of the at least oneexpandable unit (21). The advantages of the present embodimentcorrespond to those listed in FIG. 11 d. The planar coupling (27, 404)also allows potentially better retention than in the embodiment in FIG.11d . It may also be placed anywhere because no pocket (50) is provided.

FIG. 11f shows a further embodiment in which the substance carrier (40)consists of at least two parts. One part may be a membrane (402) towhich a substance (403) may be applied. The substance carrier (40) mayalso consist of at least one fixing component (406). The further atleast one fixing component (406) of the substance carrier (40) may serveto position and fix the membrane (402) on the inside of the sleeve (2)and/or the end face of the at least one expandable unit (21). In theembodiment shown, the at least one fixing component (406) is provided asa flat, frame-like component. The at least one fixing component (406)may be formed like a frame (401) according to the previous description,with the special feature that the membrane (402) to which the substance(403) is applied and the frame (401) are connected to one another onlyon insertion into the sleeve (2)/onto the expandable unit (21). Theunderside of the at least one fixing component (406) may at leastpartially overlap with the top of the membrane (402). As a result ofthis at least partial overlapping, the membrane (402) may be affixed tothe surface of the sleeve (2) and/or the end face of the at least oneexpandable unit (21). The underside of the at least one fixing component(406) may be connected to the inside of the sleeve (2) and/or the endface of the at least one expandable unit (21) by means of at least onecoupling (27, 406). The at least one coupling (27, 406) may be designedas a plug connection or as an adhesive connection. The at least oneadhesive connection (27, 406) may be produced in the form of aself-adhesive film which may be connected to the surface of the sleeve(2) and/or the end face of the at least one expandable unit (21). Theself-adhesive film may consist of a base layer, an adhesive layer and aprotective film which protects the adhesive layer for example fromcontact with water. The base layer may consist of polyurethane, siliconeor polytetrafluoroethylene (PTFE). A silane layer may possibly be usedas a single-component adhesive layer in a self-adhesive film. Otherkinds of adhesive connection are also conceivable. The hardening takesplace after removal of the removable protective layer in moistsurroundings through water. The at least one coupling may also becarried out through at least one button-eyelet connection or at leastone Velcro fastening connection.

In respect of each of the abovementioned embodiments, the substancecarrier (40) may be provided with the substance (403) only directlybefore implantation of the implant under operating conditions by aperson in the operating theatre, and may then be inserted into thedevice, for example into a pocket (50), onto the inside of a sleeve (2)and/or onto the end side of an expandable unit (21). Alternatively, asubstance carrier (40) already provided with a substance (403) may beused and the latter may be inserted into the device under operatingconditions. Alternatively, the substance carrier (40) may be insertedinto a pocket (50), into the sleeve (2) and/or onto the end side of anexpandable unit (21) right during production of the device and may beprovided with a substance (403) during production of the device or at alater time, for example before implantation of the device. Irrespectiveof the degree of preparation of the substance carrier (40)/of thedevice, pretreatment of the substance carrier (40) and/or of thesubstance (403) may be required before implantation of the device.Pretreatment of the substance (403) and/or of the substance carrier (40)may involve flushing with a buffer (for example Phosphate BufferedSaline, PBS) to set a specific pH value, flushing with a nutrientsolution, setting a temperature or a combination thereof. Alternatively,a device with a substance carrier (40) on which no substance (403) isyet provided may also be implanted. The substance (403) may then beadded after implantation has been carried out. Details of this areprovided in a subsequent section. An advantage of this embodiment is thedivision of functions into a pure substance carrier (40) and a fasteningframe (406), which may make production of the individual parts lesscomplex and also simplify handling upon use.

A further embodiment of the substance carrier (40) may be porous. Thesubstance carrier (40) may therefore store the substance (403) within itlike a sponge and release it, for example, when pressure is applied.Through the enlarged surface area and through the use of biocompatiblematerials or a biocompatible coating, the substance carrier (40) in suchan embodiment may also be provided with living cells which may transferfrom it to the surface of the heart, for example if it is in permanentcontact with the latter.

The substance carrier (40) may comprise at least one sensor and/or atleast one electrode. The sensor here may be a temperature sensor, apressure sensor, a pH sensor, an oxygen sensor, a CO₂ sensor, an opticalsensor, a conductivity sensor or an impedance sensor. Possible functionsof the sensors are mentioned in a previous section. With the aid of asensor, the conditions on and around the substance carrier (40) may bedetected in order, for example, to indicate whether contact is beingmade with the surface of the heart.

The substance carrier (40) may also comprise at least one radiopaquemarking (407) by means of which the position of the substance carrier(40) during and after implantation may be checked. Alternatively, or inaddition, the pocket (50) may comprise a radiopaque marking (505).

FIGS. 12a and b show two embodiments of the implant (100). A partialsection through the sleeve (2) provides a better view of the substancecarrier (40) which is affixed to the at least one expandable unit (21).The at least one expandable unit (21) may be provided with a deliveryand discharge line (213).

FIG. 12a shows an embodiment of the implant (100) in which the substancecarrier (40) without a pocket (50) may be affixed directly onto the endface of the at least one expandable unit (21). The fixing may be carriedout with the aid of in this case punctiform couplings (27, 404). Thepunctiform couplings (27, 404) may be plug connections, button-eyeletconnections or adhesive connections, or alternatively Velcro fasteningconnections. The substance carrier (40) may consist of a membrane (402)and comprise a substance (403) applied thereto. Alternatively, thesubstance carrier (40) may have a frame (401) over which a membrane(402) is stretched, onto which in turn the substance (403) may beapplied. Embodiments of a substance carrier (40) differing herefrom arealso conceivable.

FIG. 12b shows an embodiment of the implant (100) in which the substancecarrier (40) may be inserted via an opening (501) into a pocket (50) andaffixed directly onto the end face of the at least one expandable unit(21). The pocket (50) may have a removable area (502) which may providea window in the pocket (50) after it has been removed. The removablearea (502) may be defined by a perforation (503) which may facilitatethe removal of the removable area (502). As a result, the substanceapplied to the substance carrier (40) may be brought into contact withthe surface of the heart through the window. The coupling of thesubstance carrier (40) to the surface of the at least one expandableunit (21) may be carried out via a planar coupling option (27, 404), forexample a planar adhesive connection to the underside of the substancecarrier (40) which at least partially covers the underside of thesubstance carrier (40). In the embodiment shown, the at least oneexpandable unit (21) is structured as an inflatable chamber. This may bean inflatable chamber which is filled with a fluid. Liquids or gases maybe used as fluids. Alternatively, the inflatable chamber may also befilled with solids (for example nanoparticle mixtures). Alternatively,the inflatable chamber may also be filled with liquids and/or gasesand/or solids. The present embodiment of the implant (100) has aninflatable unit which may be filled with a gas mixture (air) and whichis supplied with a gas mixture via a pneumatic line (213). The pneumaticline (213) may be passed through the fixing sleeve (41) and the cableharness (4) here.

FIG. 13 shows an embodiment of the at least one substance carrier (40)of the implant in the form of a container (40), a substance deliveryline (408), a substance discharge line (409), a sensor (4010) and anadjuster (4011).

The material of the substance carrier (40) may be the same as that ofthe at least one expandable unit (21). A different material therefrommay also be chosen. Possible materials are specified elsewhere. For thepurposes of delivering, replacing and/or refilling substance (403) intothe device in the implanted state, the device may also contain at leastone substance delivery line (408). In order to discharge old, used ortherapeutically no longer active substance (403) from the implanteddevice or else for the purposes of flushing the substance carrier (40)and/or the membrane, the device may also contain at least one substancedischarge line (409). The at least one substance delivery line (408)and/or substance discharge line (409) may in each case end outside thebody. In this embodiment, the substance carrier (40) may, afterimplantation, be filled from outside the body with the substance (403)itself or with a liquid which contains the at least one substance (403).In the exemplary embodiment shown, the substance carrier (40) may befilled via a manual delivery device (4014), for example a syringe, whichcontains the substance (403). Machine-controlled delivery is alsoconceivable. The substance carrier (40) may have at least one dischargeline (409) via which a liquid may be removed from inside the substancecarrier (40). The substance carrier (40) may be emptied from outside thebody. The possibility of at least partially filling and emptying fromoutside the body may serve to set the quantity of the at least onesubstance (403), to set the concentration in the event that thesubstance (403) is an active agent, or to replace the liquid containingthe substance (403). The at least one substance carrier (40) may alsoonly have a shared substance delivery and discharge line. The at leastone substance delivery line (408) and/or the at least one substancedischarge line (409) may also be fed out of the body in the cableharness. The plug parts on the cable harness may contain ports for theconnection of substance lines and the substance lines may be connectedto these ports. The plug parts may be connected to a supply unit. Thedelivery or discharge of substance (403) from a substance carrier (40)may also be regulated through the supply unit. The supply unit maycorrespondingly contain, for this purpose, a substance reservoir, a feedpump and/or a pressure reservoir, valves and electric components forcontrolling the components, for example a microcontroller.

The substance carrier (40) may have a removable area (502) on its endface which may be removed and which may provide a window into the insideof the substance carrier (40). Through the window, the contents of thesubstance carrier (40) may come into contact with the surface of theheart or the inside of the pericardial cavity. The removable area (502)of the substance carrier (40) may be removed from the substance carrier(40) via a device provided for that purpose from a locationally remotepoint. This point may lie outside the body. A mechanism may lead to theremoval of the removable area on the substance carrier (40).

In FIG. 13, this mechanism is designed with the aid of cords (504).Exemplary embodiments may comprise at least one cord provided to removethe removable area, a thread or a cable, for example as part of a cablecontrol. Alternative mechanisms are also conceivable. In the presentexemplary embodiment, two cords (504) are connected to those corners ofthe removable area (502) lying at the top. The removable area of thesubstance carrier (40) may be removed by pulling on the cords (504). Thecords (504) may be designed as part of the cable harness and may bepulled from outside the body. The position of the removable area afterremoval from the substance carrier (40) may be in a cavity in the fixingsleeve lying inside the epicardium. Alternatively, the removable area(502) is made, as described above, at least partially out of abiodegradable and/or permeable material. Further characteristics of theremovable area are described in previous sections.

The substance carrier (40) may also be designed as at least one fillableand/or emptyable container for storing substance (403). The at least onecontainer may alternatively also be coupled directly to a substancecarrier (40) so that substance (403) may transfer from the container(40) onto the membrane. For example, a container (40) may be locateddirectly on the back of a substance carrier (40) and the coupling pointmay be arranged to be permeable or perforated. If the container (40) isnot in direct contact with a substance carrier (40), asubstance-conducting connection from the container (40) to the membranemay also be produced through a channel or hose. The container (40) mayhave at least one delivery line (408) through which a substance (403) ora fluid which contains the at least one substance (403) to be insertedmay be delivered into the container (40). The container (40) may alsohave a discharge line (409) via which substance (403) may be removedfrom the container (40) out of the body.

The substance carrier (40) may also comprise at least one sensor (4010).The at least one sensor (4010) may detect a parameter of the substancecarrier (40) and/or of the content of the substance carrier (40).Variables detectable through the at least one sensor (4010) may be thecompressive or tensile stress in the substance carrier (40), the pHvalue, the temperature, an electric voltage, the osmolarity, the oxygenconcentration, the CO₂ concentration, the electrical conductivity, theoptical density, an active agent concentration, the presence of liquidand/or substance (403) or a combination thereof. The position of the atleast one sensor (4010) on the substance carrier (40) may be such herethat it enables optimal detection of the parameter of the substancecarrier (40) and/or of the substance (403) contained therein to bedetected.

The substance carrier (40) may also comprise at least one adjuster(4011) to influence at least one parameter of the substance carrier (40)and/or of the substance (403). In the present exemplary embodiment, aheating coil (4011) is shown by way of example. The at least one heatingcoil (4011) may be used to adjust the temperature in the substance (403)or on the substance carrier (40). It is possible hereby to influence,for example, the growth conditions for living biological cells.

The substance carrier (40) may comprise at least two electrodes (4012)which may be connected to a supply unit via electric lines (4013). Thetwo electrodes (4012) may be an adjuster (4011). Via the electrodes(4012), an electrical voltage may be applied to the substance carrier(40), the membrane and/or the liquid located in the substance carrier(40) which contains the substance (403). The application of anelectrical voltage may change the characteristics of the substance (403)located in the substance carrier (40). The application of an electricalvoltage may influence the growth of living biological cells located inthe substance carrier (40).

In FIG. 13, the substance carrier (40) is affixed to the end side of anexpandable unit (21). With the aid of the expandable unit (21), contactmay be made between the substance carrier (40) or its contents and thesurface of the heart by filling and emptying the expandable unit (21).With the aid of the at least one expandable unit (21) to which thesubstance carrier (40) is affixed, the contact pressure of the substancecarrier (40) against the surface of the heart may be set by deliveringand discharging a fluid via the pneumatic line (213). With the aid ofthe at least one expandable unit (21) to which the substance carrier(40) is affixed, the contact pressure of the substance carrier (40)against the surface of the heart may be adjusted as required. If theexpandable unit (21) is, for example, structured as an inflatablechamber, the contact pressure against the surface of the heart may beregulated by delivering or discharging a pressurized fluid via the line(213). The filling with fluid or the discharging of the fluid may beregulated so that constant contact pressure of the substance carrier(40) against the heart muscle always prevails. Alternatively, temporallyand periodically alternating pressure patterns may also be applied. Forexample, a lower contact pressure may be applied during the systole thanduring the diastole or correspondingly conversely. This has theadvantage that the behaviour of the body's own cells and of thetherapeutic (stem) cells may be influenced as a function of the contactpressure and therapeutic efficiency may therefore be improved.

FIGS. 14a to d show various embodiments of a substance carrier (40)which may be exposed to a mechanical load. A mechanical load on thesubstance carrier (40) may lead to a mechanical load on the membrane(402) and the substrate located thereon. If the substrate containsliving cells, different what are referred to as cytokines may besecreted if cell physiology is influenced owing to the mechanical load.Depending on the cytokines secreted from the cells, it may be possible,for example, to regulate therapeutic efficiency in order to regenerateischaemic myocardium tissue after a myocardial infarction.

FIGS. 14a and b show exemplary embodiments in which the tensile stressof the substance carrier (40) may be set via a mechanical adjustmentmechanism (4017) in the form of coupling elements (4015), a fractionelement (4016) and a winder (4017). The substance carrier (40) may becoupled to the frame structure (1). This coupling may be produced inthis exemplary embodiment through coupling elements, for example throughat least one strut, a thread, a cable or at least one wire. The at leastone coupling element is affixed to a substance carrier (40) and may becoupled at the end thereof to the frame structure (1), in particular toa frame segment running along the circumference. A traction element(4016), for example a wire, a thread or a plastic strip, may also beaffixed to the substance carrier (40), the other end of which tractionelement (4016) is coupled to a winder. Via the winder, the state ofaxial stress of the substance carrier (40) may be set. Through settingof the state of axial stress, the growth of living biological cellslocated on the substance carrier (40) and the physiology of the livingbiological cells may be influenced. Via the winder, a tensile stress maybe applied to one end of the substance carrier (40). Depending on theembodiment of the cable control, a tensile stress may also be appliedvia the winder to both ends of the substance carrier (40). The tensilestress may be constant. The tensile stress may also be transient inorder, for example, to produce a pulsatile stress similar to aphysiological stress.

FIG. 14c shows a further embodiment of a device for setting themechanical load on the substance carrier (40) with the aid of anexpandable unit (21). The substance carrier (40) may be mounted via anexpandable unit (21) which may be incorporated into the sleeve (2). Inthe present exemplary embodiment, the expandable unit (21) for adjustingthe mechanical load is represented as an inflatable chamber. Anexpandable unit (21) may press the substance carrier (40) against thesurface of the heart. The substance carrier (40) may also be larger thanan expandable unit, whereby the expandable unit (21) may be at leastpartially covered by the substance carrier (40). In this case, anexpansion of the expandable unit leads to an elongation of the substancecarrier (40) and/or the substance carrier (402) and the substance (403)located thereon, as a result of which mechanical load may be built up.The amount of the elongation and/or stress produced may be regulated viathe stroke of the expansion of the expandable unit (21).

FIG. 14d shows an exemplary embodiment of a substance carrier (40) whichmay be exposed to a mechanical load. The substance carrier (40) may beaffixed prestressed to the sleeve (2) and/or the end face of the atleast one expandable unit (21). The substance carrier (40) may have, onits underside, at least one planar coupling element with which apreferably materially bonded connection between the substance carrier(40) and the surface of the sleeve (2) and/or the at least oneexpandable unit (21) may be formed. The materially bonded connection maybe an adhesive connection. The state of stress may be set in a targetedmanner through at least one marking (28) applied to the surface of thesleeve (2) and/or the end face of the at least one expandable unit (21).This at least one marking (28) may indicate how far the substancecarrier (40) has to be elongated in order to build up the stress to beset. The at least one marking (28) may indicate a distance. The at leastone marking (28) may also copy the outlines of the elongated substancecarrier (40) so that the elongation state to be set during fixing isassured. Alternatively, to fix the prestressed substance carrier (40),positive connection may also be used in order to produce the state ofstress to be set. The positive connection may be a button-eyeletconnection, a push-button connection, a Velcro fastening connection or ahook-eyelet connection between the coupling elements (27, 404). Tofacilitate elongation of the substance carrier (40), grips may beprovided in the form of loops or wings on the substance carrier (40)which cannot undergo any coupling with the surface of the sleeve. It istherefore possible to pull on these grips without impairing the couplingsurface or coupling points through contact with the skin.

FIG. 15 shows an embodiment of the at least one actuator unit (51) whichmay set the volume of the at least one expandable unit (21) via thepneumatic line (213). Embodiments of the device according to theinvention may have at least one actuator unit (51). An embodiment of theactuator unit (51) is represented which may comprise a reservoir space(513) filled with a fluid and surrounded by a membrane (512) (this fluidmay be a gas and/or a liquid), a drive unit (514) (which may be anelectric motor or a pneumatic unit), a connecting rod (515) and a piston(516). The reservoir space (513) may be delimited by a membrane (512).This membrane (512) may be elastic. The membrane (512) may be made outof the same material as the at least one expandable unit (21). Themembrane (512) may also be made out of a different material from the atleast one expandable unit (21). The membrane (512) may be made out ofpolyurethane, silicone or polytetrafluoroethylene. The membrane (512)may be ellipsoid in shape. The membrane (512) may also be other thanellipsoid in shape. The piston (516) may be part of the membrane (512).The piston (516) may also be designed as a separate part. The reservoirspace (513) is connected to the space of the at least one expandableunit (21) via a line. The reservoir space (513) may lie outside thebody. The reservoir space (513) may also lie inside the body. Thereservoir space (513) may be accommodated in the supply unit. The spaceof the at least one expandable unit (21) of the implant may be thechamber space (215) of an inflatable, bellows-like chamber. Thereservoir space (513) may be larger than the chamber space (215). Theoverall space, consisting of the reservoir space (513), the chamberspace (215) and the line space, is sealed and filled with a fluid. Thefluid may be a gas and/or a liquid.

The piston (516) may reduce the reservoir space (513). The piston (516)may reduce the reservoir space (513) by pressing in the membrane (512).The piston (516) may press in or release the membrane (512) through atranslational movement. The pressing in or the releasing of the membrane(512) by the piston (516) may also be achieved through a movement of thepiston (516) differing from a translational movement. The pressing in orthe releasing of the membrane (512) may be achieved through acombination of translational and rotatory movements. By changing thereservoir space (513), the chamber space (215) may be changed owing tothe sealed nature of the overall space. As a result, the pressureexerted by the at least one expandable unit (21) on the surface of theheart may be set.

The piston (516) may be moved by means of a device provided for thatpurpose and made to press in or release the membrane (512) of thereservoir space (513). The device may be an eccentric disc. This devicemay also differ in shape from an eccentric disc. This device may be acrankshaft. The device may carry out a rotatory movement for thepurposes of moving the piston (516). The device may also carry out atranslational movement or a combination of translational and rotatorymovements for the purposes of moving the piston (516). Through movementof the device, the piston (516) may be moved and this may change thereservoir space.

The device may also be identical to the piston (516). In such anembodiment, the device may be used to change the reservoir space (513).

An embodiment of the drive unit (514) of the at least one expandableunit (21) may comprise a device for moving the piston (516). This devicefor moving the piston (516) may be an eccentric disc which may be movedby means of a motor unit. This motor unit may be an electric motor. Themotor unit may also be a pneumatic unit. The eccentric disc may bepositioned on the drive shaft of the motor unit. The drive shaft of themotor unit may rotate axially. The control variable of the motor unitmay be the speed of the shaft. The control variable of the motor unitmay also be a translational stroke. The motor unit may change thereservoir space (513) through a translational stroke movement. The motorunit may set a temporally constant stroke. The motor unit may also set atemporally variable stroke.

One embodiment of the actuator unit (51) may also have a further optionfor setting (517) the reservoir space (513). This setting option (517)may be static. The setting option may be a stroke element. In thepresent embodiment, the stroke element (517) may be adjusted via arotary button (518). The setting of the stroke element (517) may also becarried out via an operating element differing from a rotary button, forexample by means of a slide control which may control the setting of thestroke element.

FIG. 15 shows an embodiment of the actuator unit (51) in which theeccentric disc is designed by means of a connecting rod (513) mountedeccentrically on the motor shaft. The position of the connecting rod(513) is set by means of a motor unit (514) which may be an electricmotor. The end of the connecting rod (513) not mounted eccentrically onthe motor shaft may be coupled to the membrane (512) of the reservoirspace (513) via an intermediate piece. The coupling may be carried outby gluing, welding or vulcanization or another joining technique or formof coupling. A change in the position of the connecting rod (513) maybring about a change in the reservoir space (513) whereby the chamberspace (215) of the at least one expandable unit (21) may change. Thereservoir space (513) may be larger than the chamber space (215). Themotor unit may be operated by means of the energy store contained in thesupply unit to supply energy to the implant.

FIG. 16 shows an embodiment of the implant (100) which may consist onlyof the frame structure (1), at least one sleeve (2), the at least oneexpandable unit (21) and at least one substance carrier (40) with atleast one substance. The implant may therefore be implanted entirelyinto the body or into the pericardial cavity (902) through a surgicalopening (903) made in the pericardium (901) without any outlet throughan artificial body opening, a pericardium sluice or a cable harnesshaving to be produced. An advantage of this embodiment is the lower riskof infection by avoiding any artificial body opening, its simpleimplantability because the pericardium may be stitched together again,and the simple structural form which may be material-saving andcost-saving.

The at least one expandable unit (21) may, for example, be a pneumaticunit in the form of a patch that may be filled with a fluid and that mayhave static pressure exerted upon it. As a result, constant contactbetween the surface of the heart and the at least one substance carrier(40) mounted on the at least one expandable unit (21) may be guaranteed.Alternatively, the expandable unit (21) may also be designed as a spongeor with the aid of a spring, for example made of nitinol, and may be setto specific degree of expansion by means of this spring.

The at least one sleeve (2) may have at least one opening (26) by meansof which the exchange of liquid within the pericardial cavity (902) maybe guaranteed. The frame structure (1) may also have an opening (15)coincidentally with the sleeve (2).

The frame structure (1) may have at least one coupling point (18) at theend near to the apex of the heart which may be removed minimallyinvasively from body with a set of explantation instruments suitable forthe purpose or an explantation device similar to the one described in aprevious section.

Further embodiments entirely implantable into the body may consist ofonly a frame structure (1) with at least one expandable unit (21) and/oronly at least one substance carrier (40) with at least one substancewithout the implant comprising a sleeve (2). Yet further embodiments mayconsist of a sleeve (2) with at least one expandable unit (21) and/oronly at least one substance carrier (40) with at least one substancewithout the implant comprising a frame structure (1). In this case, thewall thickness of the sleeve (2) may be arranged to be so thick that thesleeve (2) alone without the frame structure (1) is sufficiently stiffto remain in the body in the correct fit. For example, such a sleeve (2)may be made out of silicone with a wall thickness of 0.5 mm to 5 mm, ora wall thickness of 1 mm to 3 mm.

In some embodiments, the implant (100) may be made in at least one partout of at least one biodegradable material. An advantage of theembodiment of part of the implant (100) made of a biodegradablematerial, for example in the case of a biodegradable frame structure(1), is the easier removal from the body because the stiff framestructure (1) no longer has to be removed from the body. An advantage ofan implant (100) made entirely out of biodegradable material is thatthere is no longer any need for explantation.

FIG. 17 shows geometries of the frame structure (1) which may bedesigned such that pointed and sharp-edged parts of the frame structure(1), which are often located at ends (19) of the frame structure (1),increase the risk of penetration through the sleeve at least partiallysurrounding the frame structure (1) or of damage to the body tissue.

FIG. 17 shows various embodiments of end fittings (60) which may serveto cover pointed or sharp-edged parts of the frame structure (1). Thismay be advantageous because the risk of penetration by the framestructure (1) through the sleeve pulled over it (not shown) may therebybe minimized. Moreover, the risk that parts of a potentially pointed orsharp-edged geometry of the frame structure (1) will damage body tissuemay be removed.

FIG. 17a shows the geometry of a frame structure (1) over which endfittings (60) may be pulled. These end fittings (60) may consist of anelastic, preferably soft material. The end fittings (60) may consist ofa plastic or a polymer. For example, the end fittings (60) may consistof silicone or polyurethane. The end fittings (60) may also consist ofmaterials other than silicone or polyurethane. The end fittings (60) mayalternatively consist of a plastic foam. The aim of the end fitting (60)is to prevent penetration by the frame structure (1) through the sleevepulled over it and/or damage caused to body tissue by the framestructure (1).

The end fittings (60) may be coupled to the frame structure (1).Coupling options are, for example, non-positive, materially bondedand/or positive connections. The end fittings (60) may, for example, beglued to the frame structure (1). They may be stuck to the framestructure (1). However, they may also be stuck together through anopening in the frame structure (1). Alternatively, fixing may also becarried out with the aid of pins or buttons (602). For a connection withbuttons, the at least two complementary coupling points (601) requiredfor this purpose may be part of the end fitting (60). Alternatively, anend fitting (60) may also only be placed at the corresponding point onthe frame structure (1) and then coupled to the sleeve, for examplestuck.

The end fittings (60) may have at least one cavity (603) which may besuitable for feeding in part of the frame structure (1). As a result,the retention of an end fitting (60) on the frame structure (1) may beimproved.

FIG. 17b shows a further embodiment of an end fitting (60) which may belaid in the form of an at least partial ring over at least part of thecircumference of the frame structure (1). The material of the endfitting (60) may be considerably elastically deformable and flexible sothat it may be converted, when inserting or removing the implant, froman expanded into a non-expanded state and vice versa without beingdamaged itself and without damaging other components or any body tissue.

FIG. 17c shows a geometry of the frame structure (1) together with anassociated end fitting (60) in which, through appropriate cutting of theinitial geometry, the slotted tube (20), an atraumatic form may beproduced. This form minimizes the risk of body tissue injury throughpenetration, impaling, cutting or scratching by the frame structure (1)and the risk of the frame structure (1) breaking through the at leastone sleeve surrounding the frame structure (1). The cutting may, forexample, be designed such that the respective last slots on at least oneend (19) of the slotted tube are arranged such that there is no longerany material connection between the struts protruding through the slots.Free-standing ends may therefore be produced. Upon widening of thestructure, during the course of which the expanded geometry (asdescribed in a previous section) is established through heat treatment,the free-standing ends of the frame structure (1) may be deformed suchthat the established geometry at the ends in the expanded state iscurved so that these ends take on an atraumatic form. In addition, thesealready atraumatically formed ends may also be covered and secured withend fittings (60) of suitable shape. The risks described above maytherefore be further reduced.

FIG. 18 shows a step during the removal of the implant (100) from thebody. An embodiment of the explantation device (70) may consist of acylindrical explantation tube (701). The explantation tube (701) has aproximal end facing the operator and a distal end which is inserted intothe patient. The cylindrical explantation tube (701) has a radialwidening at the distal end. The explantation device (70) may alsoconsist of a traction element (704) with an external thread with a clamp(705) at the distal end of the traction element (704), an end fitting(702) with an axial bore and a nut (703).

As shown in FIG. 18, thoracotomy or a mini-thoracotomy allows access tothe implanted device. The sealing of a pericardium opening (903)guaranteed by a pericardium sluice (3) may be removed in order toposition the explantation device. The pericardium sluice (3) may remainin its position in the body here as it does not obstruct theexplantation process. Alternatively, the pericardium sluice (3) may beremoved as it is not otherwise required for the explantation. At leastpart of the cable harness (4) may be separated off to facilitate theprocedure, for example by cutting away or clipping off. For explantationof the implant (100), the explantation tube (701) may first be insertedinto the body so that the distal end of the tube is located inside thepericardial cavity and/or, if there is one, a pericardium sluice (3).The cable harness (4) leading away from the implant (100) or theremaining part of a separated cable harness (4) may be passed throughthe inside of the explantation tube (701). A fraction element (704) maybe passed into the explantation tube (701) from outside. The tractionelement (704) may have an inner lumen through which at least part of thecable harness (4) may be passed. The traction element (704) may comprisea thread, for example an external thread. At the front end of thetraction element (704) there may be a clamp (705) which at leastpartially surrounds the cable harness (4) and may be firmly coupled tothe cable harness (4). Alternatively to the clamp (705) on the cableharness (4), a clamping device may also be located on the tractionelement (704), it being possible for this clamping device to be coupledto the fixing sleeve (41) of the cable harness (4). The traction element(704) and the clamp (705) may be two or more parts, but may also consistof just one part. The explantation device (70) may also comprise an endfitting (702) with an opening, for example a bore, which may be placedat the proximal end of the explantation tube (701). The end fitting(702) may be coupled to the explantation tube (701), for example withthe aid of a centring pin (706), such that the end fitting (702) cannotbe twisted towards the explantation tube (701). The traction element(704) may be fed through the opening in the end fitting (702). Thetraction element (704) and the end fitting (702) may be secured againsttwisting towards one another. The explantation device may also contain anut (703), for example a milled nut, which has an internal thread whichmay be brought into engagement with the external thread of the tractionelement (704). By turning the nut (703), a tensile force may be exertedon the traction element (704) here which is in turn coupled to the cableharness (4)/the implant (100) and which serves to pull the implant (100)into the explantation tube (701). The advantage of this explantationdevice (70) is that the tensile force required is exerted by the nut(703), the fraction element (704) and the clamp (705) on the implant(100) and the counterforce is applied as compressive force by theimplant (100) on the explantation tube, the end fitting (702) and thenut (703). The explantation device (70) is therefore outwardlyforce-free, that is to say no forces are exerted on the heart or thebody of the patient during explantation (for example for support or thelike). When the implant (100) is then located far enough inside theexplantation tube (701), the entire explantation device (70) togetherwith the implant (100) may be removed from the body. The pericardium andthe thoracotomy required for explantation may then be suitably closed.

As shown in FIG. 18, the distal end of the explantation tube (701) maybe fed through the pericardium sluice (3) into the pericardial cavity.The inside of the explantation tube (701) defines the explantationchannel into which the implant (100) is at least partially pulled duringexplantation. For the purposes of explantation, the implant (100) may beconverted into a compressed state. The explantation tube (701) may havea radial, funnel-shaped widening at the distal end. This widening allowsexplantation of the implant (100) with low risk of injury because, forexample, parts of the implant (100) are prevented from catching, jammingand/or becoming blocked at the distal end. The widening may also serveto compress the implant (100) in a defined manner when it is pulled intothe explantation tube (701). The angle of opening of the radial wideningmay be between 0° and 150°, between 10° and 90° or between 20° and 60°.The length of the explantation tube (701) may be between 4 cm and 40 cm,or between 6 cm and 25 cm. The length of the explantation tube (701) maybe chosen so that the implant (100) may be partially or entirelyaccommodated in the tube in the compressed state. The internal diameterof the explantation tube (701) may be between 2 cm and 5 cm, or between3 cm and 4 cm. The wall thickness of the explantation tube (701) may bebetween 0.1 mm and 3 mm, or between 0.5 mm and 1.5 mm. The wallthickness may decline towards the distal end of the explantation tube(701) in order to facilitate the pulling of the implant (100) into theexplantation tube (701). The clamp (705) may be designed as at least asingle part. However, it may also be designed to be multi-part so thatit may be laid around the cable harness (4) or the fixing sleeve. Theinternal diameter of the clamp (705) may be at least as large as theexternal diameter of the cable harness or of the fixing sleeve. Theinternal diameter of the clamp (705) may be variable. The clamp (705)may be designed similarly to a hose clamp. For example, a clamp (705)may be used which has an internal diameter that is larger than theexternal diameter of the cable harness (4) or of the fixing sleeve sothat the clamp (705) can easily be fed over the cable harness (4) or thefixing sleeve. As soon as the clamp (705) is then able to sit in thesought position, the internal diameter may then be reduced in order tocouple the clamp (705) to the cable harness (4)/to the fixing sleeve,for example similarly to the functional principle of a hose clamp. Byreducing the diameter, the seating and the slip resistance of the clamp(705) in relation to the cable harness (4)/the fixing sleeve to begripped may be increased. An additional improvement in relation toseating and the slip resistance may be achieved by structuring theinternal wall of the clamp (705), for example in the form of teeth,prongs or grooves. The wall thickness of the clamp (705) may be between0.1 mm and 2 mm, or between 0.3 mm and 1 mm. In the embodiment shown inFIG. 18, the clamp (705) and the traction element (704) are designed asone part. Alternatively, the traction element (704) with the clamp (705)may be designed similarly to a collet through which the cable harness(4) may be fed. The longitudinal fraction element (704) with the clamp(705) may have at least one slot in the longitudinal direction startingat the distal end here, the slot extending over at least a quarter ofthe total length of the traction element (704). The external diameter ofthe traction element (704) in the slotted area may increase towards thedistal end here so that the slotted area of the fraction element (704)is compressed upon screwing into the end fitting (702) and, for example,the cable harness (4) or the fixing sleeve is clamped. This embodimenthas the advantage that the clamp (705) does not have to be manuallyclamped to part of the implant (100) by the operator because a clamp(705) in the form of a collet automatically compresses as soon as theslotted area of the traction element (704) with an increasing externaldiameter is compressed by the end fitting (702) of the explantationdevice (70). The further the slotted traction element (704) is screwedinto the end fitting (702) here, the greater the clamping force maybecome.

The aim of the end fitting (702), amongst other things, is to preventany relative twisting of the explantation tube (701) and tractionelement (704) with respect to one another and to convert a turning ofthe nut (703) into a translational movement of the fraction element(704), for example, by means of a tongue-and-groove connection, as shownin FIG. 18, in which the traction element (704) has a longitudinalgroove into which a nib of the end fitting (702) engages. Alternatively,the end fitting (702) may, instead of a nib, also have a slot nut or adifferent guide element. The end fitting (702) may not twist towards theexplantation tube (701) either. Without the end fitting (702), theturning of the nut (703) could cause a twisting of the traction element(704) which could cause a twisting of the implant (100) and possibleinjury of the patient. The end fitting (702) is designed as at least asingle part. However, it may also be designed to be multi-part so thatit may more easily be laid around the cable harness (4). The end fitting(702) may be coupled to the proximal end of the explantation tube (701),for example through centred positioning, screwing or a bayonet catch. Inthe embodiment of the explantation device (70) shown, the clamp (705)with the traction element (704) protrudes through the centric axial boreof the end fitting (702). The coupling of the end fitting (702) to theexplantation tube (701) may be secured against the relative twisting ofthe explantation tube (701) and end fitting (702), for example through acentring pin, a splint, a screw, a bolt or a groove into which anengagement element may be coupled. The diameter of the centric axialbore may be of the order of size of the external diameter of thetraction element (704). The external diameters of the end fitting (702)shown in the drawing are similar to the diameters of the explantationtube (701) such that a secure seating of the end fitting (702) on theexplantation tube (701) is guaranteed. The turnable nut (703) may now bescrewed onto the cable harness clamp. As soon as the nut (703) comesinto contact with the end fitting (702), the implanted device(consisting of the fixing sleeve, the frame structure, the sleevelocated therein, the expandable units, lines, sensors, etc.) may bepulled out of the pericardium through successive turns on the nut (703).The external diameter of the nut (703) should allow the comfortableoperation of the explantation device (70) so that an adult is able togrip at least half of it with one hand. The external diameter of the nut(703) may be between 3 cm and 15 cm, or between 6 cm and 12 cm. Theheight of the nut (703) may be between 5 mm and 50 mm, or between 10 mmand 30 mm. The thread which allows the explantation should be designedsuch that the implant (100) may be removed by means of a number of turnsof the milled nut that is reasonable for the operator. The thread may bea single- or multi-start thread. By using a multi-start thread, thethread pitch may be increased, whereby each turn of the nut (703)transmits a greater translational movement to the fraction element(704). The thread may be a transmission thread, for example atrapezoidal thread. Transmission threads, unlike fastening threads, havethe advantage that the frictional forces are lower and/or noself-retention occurs, so the nut (703) may be turned more easily by theoperator than in the case of a fastening thread (such as a metric orimperial coarse-pitch thread). The explantation using the presentembodiment of an explantation device (70) has the advantage that thescrewing mechanism allows gradual explantation that does not rely onlarge translational movements of the explantation device (70), which inturn reduces the trauma for the patient.

Alternatively to the explantation process described above, the cableharness (4) may also be cut at the ends of the extension struts. In thecase of embodiments of the implant (100) in which the extension struts,as described in a previous section, have hooks, eyelets, loops or angledends at their ends, the implant (100) may be pulled out thereon. Anembodiment of the explantation device (70) may be used for that purposewhich alternatively or in addition to the clamp (705) on the tractionelement (704) also has cable controls, wires and/or levers. The cablecontrols, cables or levers may be part of the traction element (704) orbe coupled to the traction element (704). At the other end, the cablecontrols, cables and/or levers of the explantation device (70) may becoupled to the hooks, eyelets, loops or angled ends of the extensionstruts. As a result, the implant (100) may, as before in the previousembodiments, be pulled at least partially into the explantation tube(701) and conveyed out of the pericardium and out of the body of thepatient.

In general terms, embodiments of the explantation device (70) may bedesigned such that they make an embodiment of the implant (100) easierto explant out of the pericardium by returning it to its non-expandedstate.

In the case of embodiments of the implant (100) in which the implant(100) without any pericardium sluice (3), cable harness (4) or supplyunit is inserted entirely into the pericardial cavity (902), the atleast one traction element (704) may, instead of a clamp (705), have acoupling option at its distal end which is complementary to the at leastone coupling option provided for the explantation on the frame structure(1) of the implant (100). The coupling may, for example, be designed asa hook-eyelet connection. Other embodiments of the coupling are alsoconceivable. A more precise description of an implant (100) which may beimplanted into the pericardial cavity (902) entirely is described inmore detail in a previous section.

Certain aspects of the invention may be formulated as the followingembodiments:

In one aspect, a device supporting the function of a heart is describedwhich comprises a frame structure and a sleeve with at least oneexpandable unit. The frame structure can comprise at least one extensionstrut. The frame structure can alternatively or in addition have arecess at its upper edge which is shaped such that the frame structuredoes not come into contact with the vena cava inferior or any otheranatomical structure. The sleeve can also have a recess whose shape,size and position can substantially coincide with the recess of theframe structure.

In another aspect, a device supporting the function of a heart isdescribed which comprises a frame structure, which can undergotransition from a non-expanded state to an expanded state. The framestructure can be self-expanding and can be inserted into a deliverysystem in its non-expanded state, and can at least partially envelope aheart in its expanded state. The frame structure can have a recess atits upper edge, the recess being shaped such that the frame structure inits implanted state does not compromise the inferior vena cava or anyother anatomical structure. The recess can have a length along the upperedge of the frame structure of 2 cm, 3 cm, 4 cm, 5 cm, 6 cm, 7 cm ormore. The recess can have a depth between 1 mm and 40 mm, in particularbetween 3 mm and 15 mm. The recess can be curved, semicircular,rectangular or polygonal. The frame structure can further comprise atleast on extension strut, in particular two, three, four, five, six ormore extension struts. The at least one extension strut can be part ofthe frame structure, in particular the extension of a wire mesh or theextension of a strut of a latticework. The at least one extension strutcan be coupled to the frame structure. The at least one extension strutcan have a length of between 1 cm and 10 cm, in particular between 4 cmand 7 cm. The sleeve can comprise a recess whose shape, size andposition can substantially coincide with the recess of the framestructure.

1. Device for the administration of a substance to a surface of theheart comprising: a frame structure, a sleeve, a substance carrier and asubstance to be administered.
 2. Device according to claim 1, furthercomprising an expandable unit.
 3. Device according to claim 2, whereinthe expandable unit is mounted on the sleeve.
 4. Device according toclaim 2, wherein the expandable unit is part of the sleeve.
 5. Deviceaccording to one of claims 2, wherein the substance carrier is mountedon the expandable unit.
 6. Device according to claim 1, wherein thesubstance carrier is mounted on the sleeve.
 7. Device according to claim1, wherein the substance carrier is a pocket.
 8. Device according toclaim 7, wherein the substance to be administered is inserted into thepocket.
 9. Device according to claim 7, wherein the substance to beadministered is inserted into the pocket on a carrier.
 10. Deviceaccording to claim 7, wherein the pocket has a removable area on thesurface of the pocket facing the heart.
 11. Device according to claim10, wherein the removable area may be removed from outside the bodyafter implantation of the device.
 12. Device according to claim 10,wherein the removable area is at least partially biodegradable. 13.Device according to claim 7, wherein the pocket comprises a permeablearea.
 14. Device according to claim 1, wherein the substance carrier hasa delivery line.
 15. Device according to claim 1, wherein the substancecarrier comprises a spongy or porous structure.
 16. Device according toclaim 1, wherein the sleeve is affixed to the frame structure. 17.Device according to claim 1, wherein the device may be implantedminimally invasively.
 18. Device according to claim 1, wherein the framestructure is made out of wire, in particular out of a wire comprising ashape memory alloy.
 19. Device according to claim 1, wherein thesubstance to be administered is a pharmaceutical active agent. 20.Device according to claim 1, wherein the substance to be administeredcomprises cells.
 21. Device according to claim 1 further comprising asupply unit.
 22. Device according to claim 21, wherein the supply unitcomprises a substance reservoir.
 23. Device for implanting the deviceaccording to claim 1, wherein the device for implanting comprises atubular delivery system.
 24. Device for implanting according to claim23, wherein the tubular delivery system has a distal end face which isslanted.
 25. Device for explanting the device according to one of theclaims 1, wherein the device for explanting comprises a cylindricaltube.
 26. Device for explanting according to claim 25, wherein thecylindrical tube comprises a radial widening at the distal end. 27.Method for producing a device for the administration of a substance ontoa surface of the heart comprising the following steps: Provision of aframe structure; Mounting of a sleeve on the frame structure; Mountingof a substance carrier; and Charging of the substance carrier with asubstance to be administered.
 28. Method according to claim 27, whereinthe substance carrier is mounted on the sleeve.
 29. Method according toclaim 27 further comprising an expandable unit.
 30. Method according toclaim 29, wherein the substance carrier is mounted on the expandableunit.
 31. Method for the administration of a substance to a surface ofthe heart comprising: inserting a device for the administration of asubstance to a surface of the heart comprising: a frame structure, asleeve, a substance carrier and a substance to be administered.
 32. Themethod of claim 31 wherein inserting the device comprises: inserting adelivery device into the body and into the pericardium; and insertingthe device for the administration of a substance to a surface of theheart into the body and into the pericardium via the delivery device.